

Huntingdon Life Sciences

HUNTINGDON LIFE SCIENCES

VINYL CHLORIDE COMBINED INHALATION TWO-GENERATION
REPRODUCTION AND DEVELOPMENTAL TOXICITY STUDY IN CD RATS

STUDY NO.: 96-4080

ISSUE NO.: 3

SUBMITTED TO: Chemical Manufacturers Association
Chemstar Department

ATTENTION: Robert Venezia, Ph.D.

DATE: October 3, 1996

1 INTRODUCTION:

- 1.1 STUDY NO.: 96-4080
- 1.2 ISSUE NO.: 3
- 1.3 STUDY TITLE: Vinyl Chloride Combined Inhalation
Two-Generation Reproduction and
Developmental Toxicity Study in CD
Rats
- 1.4 TEST MATERIAL: Vinyl Chloride
- 1.5 SPONSOR: Chemical Manufacturers
Association
Chemstar Department
1300 Wilson Boulevard
Arlington, Virginia 22209
- 1.6 SPONSOR REPRESENTATIVE: Robert A. Venezia, Ph.D.
Phone - 703-741-5639
Fax - 703-741-6091
- 1.7 TESTING FACILITY: Huntingdon Life Sciences
Mettlers Road
P.O. Box 2360
East Millstone, NJ 08875-2360
- 1.8 PURPOSE:

The objectives of the combined inhalation two-generation reproduction and developmental toxicity study outlined in this protocol are to evaluate the effects of the test material on parental toxicity, reproductive capability, in utero development, and neonatal growth and survival in rats.

2 STUDY PERSONNEL:

Study Director:	Raymond E. Schroeder, M.S., DABT
Alternate:	Dean E. Rodwell, M.S. Vice-President of Toxicology
Director of Toxicology:	Carol S. Auletta, B.A., DABT
Inhalation Toxicologist:	Gary M. Hoffman, B.A., DABT
Supervisor Rodent Toxicology:	Ellen Whiting, AALAS LAT
Primary Technician:	*
Vice President, Pathology:	Ward R. Richter, D.V.M., M.S., ACVP
Study Pathologist:	*
Director, Quality Assurance & Regulatory Affairs:	Michael Caulfield

Additional personnel will be documented in the project file and presented in the final report.

3 REGULATORY REFERENCES:

3.1 TEST GUIDELINE:

This study is designed to meet or exceed the guideline requirements of the following:

- EPA (Environmental Protection Agency: TSCA Test Guidelines (EPA, 1985);
- Organization for Economic Co-operation and Development (OECD, Guidelines for testing of chemicals, Section 4: Health Effects, (OECD, 1981); and
- European Economic Community (EEC), Methods for the Determination of Toxicity (EEC, 1988).

*to be determined

3.2 GOOD LABORATORY PRACTICES:

This study will be conducted in compliance with the following:

- FDA (Food and Drug Administration) Good Laboratory Practice (GLP) Regulations for Nonclinical Studies (FDA, 1988 - Part 58 of 21 CFR);
- EPA TSCA Good Laboratory Practice Standards (EPA, 1990 - Part 160 of 40 CFR);
- OECD Good Laboratory Practice Procedures (OECD, 1982 - Annex 2 C [81] 30 [FINAL]);
- Standard operating procedures of the Testing Facility

3.3 FACILITIES MANAGEMENT/ANIMAL HUSBANDRY:

Currently acceptable practices of good animal husbandry will be followed, e.g., Guide for the Care and Use of Laboratory Animals; DHHS Publication No. (NIH) 86-23, Revised 1985. Huntingdon Life Sciences (East Millstone, NJ) is fully accredited by the American Association for Accreditation of Laboratory Animal Care (AAALAC).

3.4 ANIMAL WELFARE ACT COMPLIANCE:

This study will comply with all appropriate parts of the Animal Welfare Act regulations: 9 CFR Parts 1 and 2 Final Rules, Federal Register, Volume 54, No. 168, August 31, 1989, pp. 36112-36163 effective October 30, 1989 and 9 CFR Part 3 Animal Welfare Standards; Final Rule, Federal Register, Volume 56, No. 32, February 15, 1991, pp. 6426-6505 effective March 18, 1991. The Sponsor should make particular note of the following:

1. The Sponsor's signature on this protocol documents for the study described, there are no generally accepted non-animal alternatives and the study does not unnecessarily duplicate previous experiments.
2. All procedures used in this study have been designed to avoid discomfort, distress and pain to the animals. All methods are described in this study protocol or in written laboratory standard operating procedures.
3. Any aspects of this study which cause more than momentary or slight pain or distress to the animals will be performed with appropriate sedatives, analgesics or anesthetics unless the withholding of these agents is justified for scientific reasons, in writing by the Sponsor and the Study Director, in which case the procedure will continue for the minimum time necessary.

3.4 ANIMAL WELFARE ACT COMPLIANCE:

4. Animals that experience severe or chronic pain or distress that cannot be relieved will be painlessly euthanatized as deemed appropriate by the Testing Facility's veterinary staff and the Study Director. The Sponsor will be advised by the Study Director of all circumstances which could lead to this action in as timely a manner as possible.
5. Methods of euthanasia used during this study are in conformance with the above referenced regulations.

4 QUALITY ASSURANCE MONITORING:

The Huntingdon Life Sciences Quality Assurance Unit (East Millstone, NJ) will monitor the facilities, equipment, personnel, methods, practices, records and controls used in this study to assure that they are in conformance with this protocol, company standard operating procedures, and the appropriate Good Laboratory Practice regulations.

5 ALTERATION OF DESIGN:

Alterations of this protocol may be made as the study progresses. No changes in the protocol will be made without the consent of the Sponsor. In the event that the Sponsor authorizes a protocol change verbally, such changes will be honored by the Testing Facility and will be followed by a written verification. All protocol modifications will be signed by the Study Director and a Sponsor representative. Any modifications potentially affecting animal welfare will also be signed by two members of the Institutional Animal Care and Use Committee prior to the modification's implementation.

6 PROPOSED STUDY DATES:

Two-generation Reproduction Study:

Initiation date:	Date Study Director Signs protocol - See Section 18.2.
Receipt of test animals:	*(to be addressed by amendment)
Initiation of exposures (P ₁): (Experimental start date)	*
Termination of exposures (P ₁):	*
Selection of the P ₂ parental animals:	*
Termination of exposures (F ₂):	*
Necropsy	
P ₁ :	*
P ₂ :	*
Experimental Termination (Date of last data collection):	*
Submission of draft final report:	*

Developmental Toxicity Study:

Receipt of test animals:	*
Initiation of mating:	*
Initiation of exposures (first Day 6 gestation):	*
Termination of exposures (last Day 19 gestation):	*
Experimental termination: (date of last data collection)	*
Submission of draft final report:	*
Study completion date:	Date final report is signed by Study Director.

7 EXPERIMENTAL DESIGN:

7.1 Two-generation Reproduction Study:

Group	Exposure Level (ppm) ^a	Number of Animals							
		Mated Adults				Microscopic Pathology Adult Generations ^b			
		P ₁		P ₂		P ₁		P ₂	
		M	F	M	F	M	F	M	F
I (control)	0 ^c	30	30	30	30	30	30	30	30
II	10	30	30	30	30	A.R.	A.R.	A.R.	A.R.
III	100	30	30	30	30	A.R.	A.R.	A.R.	A.R.
IV	1100	30	30	30	30	30	30	30	30

^a Whole body exposure 5 days/week, 6 hrs/day during the premating periods (P₁, F₁) and 7 days/week, 6 hrs/day for all other periods. Animals will be exposed in a glass and stainless steel inhalation chamber.

^b Histologic examinations will be performed for tissues listed in Appendix A.

^c Control animals will be chamber-housed and sham-treated with clean room air for a comparable period of time as the test animals.

Key: A.R. = As Required: 1) tissues that demonstrate treatment-related histologic changes in Group IV (additional cost); 2) gross lesions from animals found dead or euthanatized in a moribund condition during the study (additional cost); and 3) gross lesions terminal animals (additional cost);

M = Male; F = Female.

7.2 Developmental Toxicity Study:

The developmental toxicity study will be performed with a unique population of animals during the exposure period for the P₁ parental animals in the two-generation reproduction study. This will be during the mating, gestation and lactation periods for the F₁ pregnancies when animals are being exposed 7 days/week, 6 hrs/day. Animals in the developmental toxicity study will be exposed in the chamber along with the animals in the two-generation reproduction study.

Group	Exposure Levels (ppm)	Treatment Schedule 6 hrs/day	Number of Animals				
			Mated	Sacrificed*	Proportion of Gestation Day 20 Fetuses/Litter Malformation/Variation Evaluations		
				Gestation Day 20	External	Soft Tissue	Skeletal
I (chamber - housed, sham air control)	0	Gestation Days 6-19	25	A.S.	All	½	½
II	10	Gestation Days 6-19	25	A.S.	All	½	½
III	100	Gestation Days 6-19	25	A.S.	All	½	½
IV	1100	Gestation Days 6-19	25	A.S.	All	½	½

* Gross postmortem examination, liver and kidneys will be weighed and preserved along with gross lesions. Microscopic examinations of these tissues will not be conducted unless deemed necessary to interpret other observations made during the study or requested by the Sponsor (additional cost).

A.S. = All Survivors

CMA 118446

8 TEST MATERIAL:

8.1 TEST MATERIAL: Vinyl Chloride

Description, lot number, storage, expiration date and handling procedures, as well as other pertinent information will be documented in the study data. Properties of the test material are presented in the Appendix B.

8.2 IDENTIFICATION OF TEST MATERIAL:

Unless otherwise noted, the identity, strength, purity, composition, stability, and method of synthesis, fabrication and/or derivation of each batch of the test material will be documented by the Sponsor before its use in the study.

8.3 ANALYSIS OF THE TEST MATERIAL:

The purity of the lot of test material used on study will be determined at the start of study, approximately 6-months into the study and at termination. These analyses will be performed by the analytical laboratory of the Testing Facility.

8.4 ARCHIVAL SAMPLES:

A small sample from the lot of test material used on study will be taken and stored in the Archives of the Testing Facility at East Millstone, NJ.

8.5 UNUSED TEST MATERIAL:

At completion of the study unused test material in the one ton pressurized cylinder will be returned to the supplier (The GEON Company, Pedricktown, NJ 08067).

9 TEST ANIMALS: Albino Rats (Outbred) VAF/Plus[®]

9.1 STRAIN:

Sprague Dawley - derived (CD[®])
[CrI: CD[®] BR]

9.2 SUPPLIER:

Charles River Laboratories
Portage, Michigan

9.3 JUSTIFICATION FOR TEST SYSTEM SELECTION:

The rat is a rodent animal model commonly utilized in reproduction and developmental toxicity studies as recommended in the referenced guidelines. In addition, a historical control data base with this strain of animal and supplier facility is available for comparative evaluation.

9.4 ANIMAL REQUIREMENTS/SPECIFICATIONS:

9.4.1 Number:

9.4.1.1 Two-generation Reproduction Study (P_1):

	<u>Total</u>	<u>Males</u>	<u>Females</u>
Placed on test	240	120	120

9.4.1.2 Developmental Toxicity Study:

Placed on test - 100 mated females (25/group).

9.4.2 Age:

9.4.2.1 Two-generation Reproduction Study (P_1):

Males and females: approximately four weeks at receipt; approximately six weeks (males will be 160 - 210 grams and females will be 125 - 175 grams at initiation of treatment). Animals outside this weight range will be used at the discretion of the Study Director.

9.4.2.2 Developmental Toxicity Study:

Females: eight weeks at receipt and at least 10 weeks (200-275 grams) at initiation of mating. Animals outside this weight range at mating will be used at the discretion of the Study Director. Females will be nulliparous and non-pregnant.

Males: in-house breeding colony used only for mating.

9.5 ACCLIMATION PERIOD:

Approximately two weeks; all animals will be checked for viability twice daily. Prior to assignment to study all animals will be examined to ascertain suitability for study.

9.6 ANIMAL HUSBANDRY:

9.6.1 Housing:

9.6.1.1 Two-generation Reproduction Study (P_1):

Animals will be housed in suspended, stainless steel cages with wire mesh fronts and floors. For the first week of acclimation, animals will be housed two/sex/cage. Thereafter, animals will be housed individually except as follows:

Mating: one male and one female co-housed nightly.

Lactation: dam with litter.

Postweaning: two littermates/sex until selection for P_2 parental generation.

During exposures, parental animals will be housed individually in suspended stainless steel wire mesh cages. Neonates will be housed 1-2/cage (littermates) until the formal initiation of the premating treatment period.

9.6.1.2 Developmental Toxicity Study:

Animals will be housed in suspended, stainless steel cages with wire mesh fronts and floors except during mating when females will be co-housed overnight with a male. During exposures, animals will be housed in suspended stainless steel wire mesh cages.

9.6.2 Food:

Certified Rodent Diet, No. 5002; (Meal) (PMI Feeds, Inc., St. Louis, MO). Each animal's cage will be fitted to retain a glass feeder cup with a stainless steel lid. Feed will be available *ad libitum* during non-exposure periods except on the evening prior to necropsy when parental animals (P_1 and P_2) will be fasted. During exposures, animals will not have access to feed.

9.6.3 Water:

Facility water supply (Elizabethtown Water Company, Westfield, NJ); without restriction during exposures and non-exposure periods, via an automated water delivery system to individual animal cages.

9.6.4 Bedding Material - Two-generation Reproduction Study:

Hardwood shaving bedding (Lab Aspen Shavings, North Eastern Products Corporation, Warrensburg, NY) will be provided for each mated female on Day 20 of gestation. Fresh bedding will be provided as needed to Day 14 of lactation.

9.6.5 Feed Analysis:

Analytical certification of batches of feed used during the study which are provided by the manufacturer, will be maintained on file at the Testing Facility. There are no known contaminants in the feed which are expected to interfere with the results of this study.

9.6.6 Water Analysis:

Monthly water analyses, provided by the supplier, will be maintained on file at the Testing Facility. Biannual chemical and microbiological analyses of water samples collected from representative rooms in this facility will be conducted to assure that water being provided meets standards specified under the EPA National Primary Drinking Water Regulations (40 CFR Part 141). Results will be maintained on file. There are no known contaminants in the water which are expected to interfere with the results of this study.

9.6.7 Bedding Analyses:

Analyses for each batch of bedding used on study provided by the supplier, will be maintained at the Testing Facility. There are no known contaminants in the bedding which are expected to interfere with the results of this study.

9.6.8 Veterinary Care:

Animals will be monitored by the technical staff for any conditions requiring possible veterinary care. If any such conditions are identified, a staff veterinarian will be notified for an examination and evaluation. Any medical veterinary intervention will be made only with approval of the staff veterinarian and the Study Director. The Sponsor will be consulted whenever possible. However, in emergency situations, decisions will be made as needed and the Sponsor will be advised as soon as possible.

rk cycle daily.

orded twice daily. Temperature in the animal room
mbers will be maintained in the range of approxi-
o the maximum extent possible.

animal quarters will be monitored and recorded once
red humidity range in the animal room is 40-70% and
exposure chambers during exposures. Humidity will be
this range to the maximum extent possible.



UDY:

tion Reproduction Study (P₁) :

als than required for the study will be purchased and accli-
als considered suitable for study on the basis of pretest
inations, body weight data and any other pretest evalua-
be randomly assigned to control or treated groups in an
o equalize mean group body weights. Individual weights of
placed on test shall not exceed $\pm 20\%$ of the mean weight
sex. Disposition of all animals not used in the study will be
ned in the study file.

pmental Toxicity Study:

females than required for the study will be purchased and accli-
d. Animals considered suitable for study on the basis of pretest
ical examinations will included into the mating phase of the study.
ales which mate will be assigned to groups daily in such a way as
most nearly equalize both the Day 0 mean body weights between
ups and the distribution of animal into groups.



9.8 ANIMAL IDENTIFICATION:

9.8.1 Two-generation Reproduction Study:

Each animal will be assigned a temporary identification number upon receipt. After selection for study (P_1 generation), each animal will be ear-tagged with a number assigned by the Testing Facility. This number plus the study number will comprise the unique identification for each study animal. Following the selection procedure (post-weaning) to identify the P_2 parental animals from the F_1 offspring, these selected animals will be ear-tagged with a unique number. If the tag is lost, it will be replaced or the animal will be tail tattooed for identification. Each animal's cage will be provided with a card which will be color-coded for dose level identification and will contain the study number and animal number.

9.8.2 Developmental Toxicity Study:

Each female will be assigned a temporary identification number upon receipt. Mated females sorted into study groups will be ear-tagged with a number assigned by the Testing Facility that will be unique from the identification numbers used in the two-generation study. This number plus the study number will comprise the unique identification for each study animal. Females will be eartagged on Day 0 of gestation as they are sorted into groups.

10 MATING, GESTATION AND LACTATION PROCEDURES:

10.1 MATING PROCEDURE:

10.1.1 Two-generation Reproduction Study (P_1 , P_2):

After animals have been exposed to the test substance for the appropriate length of time (premating treatment period), one male and one female of equivalent dose levels will be caged together nightly (same animals) until a sign of mating (microscopic observation of sperm in the vaginal smear and/or a copulation plug in the vagina) is observed or for 14 consecutive days. The day evidence of mating is observed will be defined as Day 0 of gestation. If mating has not occurred after this interval, the animals will be separated without further opportunity for mating. During mating of the F_1 generation cohabitation of male and female littermates will be avoided.

10.1.2 Developmental Toxicity Study:

Females selected for mating will be placed with breeder males nightly in a 1:1 ratio. Vaginal smears will be taken early in the morning following nightly interval of co-housing and females will be considered to have mated if sperm is observed microscopically in the vaginal smear and/or a vaginal plug is observed. The day on which evidence of mating is observed will be defined as Day 0 of gestation.

10.2 PARTURITION AND LACTATION - TWO-GENERATION REPRODUCTION STUDY (P_1 and P_2):

On Day 20 of gestation, several days prior to expected parturition, each mated female's cage will be fitted to retain a stainless steel floor pan and bedding material provided. Examination for signs of parturition will be made twice daily (morning and afternoon). Evidence of difficult or prolonged parturition, if observed, will be recorded. The day on which all pups have been delivered will be defined as Day 0 of lactation. For females which were caged with males but exhibited no evidence of mating, preparations for undetermined pregnancies (i.e., floor pan, bedding material) will be made when the first animals mated reach their day 20 of gestation.

10.3 SELECTION OF P_2 PARENTAL GENERATION:

At weaning of each F_1 litter, two pups/sex/litter will be chosen at random to become a pool of animals from which the P_2 parental generation will be selected. Pups as chosen will be housed two littermates of the same sex/cage. After weaning of the last F_1 litter, 30 F_1 pups/sex/group will be selected from this pool of animals to become the P_2 parental animals. In this selection procedure, each litter will contribute at least one pup/sex, when possible, so as to maximize the representation of animals from different litters in each group.

After the last litter is weaned, the 30 F_1 pups/sex/group designated for the P_2 parental generation will formally initiate the premating treatment period. Thus, there may be a maximum of two weeks difference in age for the P_2 animals within each treatment group at initiation of the premating growth period. During this postweaning period, the pool of F_1 pups will be chambered and exposed (6 hrs/day) at the treatment level of the dam.

In the selection procedure, grossly malformed or obviously-diseased animals within the litters will be excluded from the pool of animals eligible for selection if, in the judgement of the Study Director, their condition may adversely affect long-term survival. Runts, if otherwise normal, will not be excluded from the selection procedure.

11 TEST MATERIAL ADMINISTRATION:

11.1 ROUTE OF ADMINISTRATION:

Inhalation (whole body).

11.2 JUSTIFICATION FOR ROUTE OF ADMINISTRATION:

The inhalation route is one of the potential routes of human exposure to this test material.

11.3 FREQUENCY OF ADMINISTRATION:

11.3.1 Two-generation Reproduction Study:

P₁ and P₂ generation animals will be exposed 6 hrs/day, five days/week for at least 10 weeks prior to mating (designated the premating treatment period). Males will continue to be exposed daily, 6 hrs/day during the 14-day mating period and postmating period until sacrificed. Females will continue to be treated daily, 6 hrs/day during mating and mated females will continue to be treated, 6 hrs/day during the ensuing gestation period through to Day 20. Treatment of females will discontinue at this point to allowed them to deliver (Day 0 of lactation) and treatment will resume on Day 4 of lactation. Females will continue to be treated (6 hrs/day) thereafter for the remainder of lactation (litters weaned on lactation Day 25) and postweaning period until sacrificed. Unmated females will continue to be treated daily (6 hrs/day) until sacrificed.

11.3.2 Developmental Toxicity Study:

Females will be treated 6 hrs/day over the Day 6-19 gestation interval. The exposure interval for these animals will coincide with the exposures for the mating/gestation/lactation periods for the F₁ litters in the two-generation reproduction study.

11.4 INHALATION EXPOSURE GENERATION PROCEDURE:

The test material will be administered as a gas in the breathing air of the animals. The test atmospheres will be generated by an appropriate procedure to be developed at the Testing Facility. The generation method will be described in the final report and maintained with the data package for this study.

The whole-body exposure chambers will have a volume of approximately 6000 liters (6 m³). Each chamber will be operated at a minimum flow rate

ATION EXPOSURE GENERATION PROCEDURE:

0 liters per minute. The final airflow will be set to provide at least one change in 5.0 minutes (12 air changes/hour) and a T_{99} equilibrium time approximately 23 minutes. This chamber size and airflow rate are dered adequate to maintain the oxygen level above 19% and the animal ng factor below 5%.


MBER MONITORING:

ominal exposure concentration will be calculated, if possible. The flow air through the chamber will be monitored using appropriate calibrated ipment. The test material consumed during the exposure will be divided the total volume of air passing through the chamber (volumetric flow rate nes total exposure time) to give the nominal concentration.

uring each test material exposure, measurements of airborne concentrations ill be made at least hourly using a MIRAN infrared spectrophotometer. Also prior to initiating of animal exposures, additional samples will be taken to determine the distribution of the test material in the exposure chamber.

During each week of exposure, particle size determinations will be performed ng an appropriate instrument to characterize the aerodynamic particle size distribution of any aerosol present.

If more than the normal amount of trialing is required because of test material generation or monitoring problems (two weeks or 150 technician hours), the Sponsor will be consulted prior to additional trialing (additional cost).



11.5 CHAMBER MONITORING:

The minimum frequency of chamber activity is summarized below:

Activity	Frequency/chamber/day
Analytical Test Material Concentration	6 times (hourly)
Temperature	7 times
Relative Humidity	7 times
Airflow Rate	7 times
Nominal Test Material Concentration (excluding the control chamber)	once
Rotation Pattern of Exposure Cages	once
Loading/Unloading Verification	once

11.6 EXPOSURE CONCENTRATIONS:

For both the two-generation reproduction and developmental toxicity studies the targeted exposure concentrations of vinyl chloride will be 0, 10, 100 and 1100 ppm. These exposure levels correspond to oral equivalent doses of approximately 0, 9.2, 92 and 1012 mg/kg/day assuming ventilation rates of 1 L/min/kg, 100 percent absorption and a 6 hr/day exposure. The high concentration of vinyl chloride was selected based on the oral equivalent of the limit dose of 1000 mg/kg body weight/day. The high exposure level of 1100 ppm is also expected to produce effects on the liver and other organ systems (ATSDR, 1993). The middle and low exposure levels were selected to provide a dose response for the observed effects and a no-observed-effect level, respectively.

12 EXPERIMENTAL EVALUATIONS:

12.1 OBSERVATIONS:

12.1.1 Viability Checks - Two-generation reproduction study and developmental toxicity study:

Observations for mortality, general appearance and signs of severe toxic or pharmacologic effects as well as availability of feed and water will be made at least twice daily (morning and afternoon). Animals in extremely poor health or in a possible moribund condition will be identified for further monitoring and possible euthanasia. All animals found dead will be submitted for a gross macroscopic examination. Parental animals found dead after normal working hours will be refrigerated until a necropsy can be performed.

12.1.2 Physical Examinations:

12.1.2.1 Two-Generation Reproduction Study:

Each animal will be removed from its cage and examined at least once pretest (P_1), at the study start (first day of treatment for the P_1 and formal initiation of the premating period for the P_2) and weekly thereafter during the study period (P_1 and P_2). Examinations will include observations of general condition, skin and fur, eyes, nose, oral cavity, abdomen and external genitalia as well as evaluations of respiration, and palpation for tissue masses. These examinations will be performed postexposure when animals are being transferred to their home cages.

12.1.2.2 Developmental Toxicity Study:

Mated animals will be given a detailed physical examination on Days 0 and 6-20 (daily) of gestation. Examinations will include observations of general condition, skin and fur, eyes, nose, oral cavity, abdomen and external genitalia as well as evaluations of respiration, and palpation for tissue masses. During the test period, these examinations will be performed postexposure when animals are being transferred to their home cages.

12.2 BODY WEIGHTS:

12.2.1 Two-generation Reproduction Study:

Males:

P₁: at the time of sorting into groups, on the day treatment initiates, weekly throughout the study and at termination.

P₂: at the formal initiation of the premating treatment period and weekly throughout the study and at termination.

Females:

P₁: at the time of sorting into groups.

P₁ and P₂: on the day treatment initiates (formal initiation of the premating period for the P₂), weekly during the premating growth periods; gestation - Days 0, 7, 14 and 20; and lactation: Days 0, 4, 7, 14, 21 and 25 (P₁ only); and at termination.

12.2.2 Developmental Toxicity Study:

Females will be weighed on Days 0, 6, 9, 12, 15 and 20 of gestation.

12.3 FOOD CONSUMPTION:

12.3.1 Two-generation Reproduction Study:

Males:

P₁: one week pretest.

P₁ and P₂: weekly during the premating treatment period and from termination of mating through to sacrifice (postmating period).

Food consumption will not be recorded during the mating periods.

Females:

P₁: one week pretest.

P₁ and P₂: weekly during the premating period; during gestation - Days 0-7, 7-14 and 14-20; during lactation - Days 1, 4, 7, 10 and 14. Food consumption will not be recorded during the mating period or postweaning period prior to termination.

12.3.2 Developmental Toxicity Study:

Food consumption will be recorded for the following intervals during Gestation: Days 0-6, 6-9, 9-12, 12-15 and 15-20.

12.4 ESTROUS CYCLE DETERMINATIONS - TWO-GENERATION REPRODUCTION STUDY:

Estrous cycle length and normality will be evaluated daily by vaginal lavage on the first 15 P₁ and P₂ females per group for the three week period prior to mating and continuing throughout the mating period or until the female is confirmed mated.

12.5 LITTER EVALUATIONS (F₁, F₂) - TWO-GENERATION REPRODUCTION STUDY:

12.5.1 Observations:

Litters will be observed as soon as possible after delivery for the number of live and dead pups and pup abnormalities (Day 0 of lactation). Thereafter, litters will be observed twice daily (morning, afternoon) for the presence of dead pups. These pups and pups euthanized in a moribund condition will be examined to the extent possible for defects and/or cause of death and preserved in 10% neutral buffered formalin. Litter size will be recorded on Days 0, 4, 7, 14, 21 (F₁ and F₂) and 25 (F₁ only) of lactation.

12.5.2 Culling:

On Day 4 of lactation, each litter with more than eight pups will be culled to that number with sex distribution equalized (four/sex) when possible. Pups will be culled using a random number table. Preferential culling of runts will not be performed. Culled pups will be examined grossly for abnormalities and following euthanasia by an overdose of inhaled carbon dioxide (CO₂) will have sex confirmed by internal inspection of the gonads. Only culled pups with abnormalities will be preserved in 10% neutral buffered formalin.

12.5.3 Physical Examinations:

Each pup will be given a gross physical examination on Days 0, 4, 7, 14, 21 and 24 (F₁ pups only).

12.5.4 Pup Body Weights and Sexing Data:

Individual pup weights and pup sexing data will be recorded on Days 0, 4 (presented for both pre- and postcull intervals), 7, 14, 21 and 25 (F₁ pups only) of lactation.

12.5.5 Physical Maturation Landmarks - Selected P₂ Animals:

All F₁ weanlings selected to become the P₂ parental animals (30 sex/group) will be observed daily for vaginal opening beginning on postnatal day 30 or preputial separation beginning on postnatal day 35. If a treatment-related effect is seen in F₁ sex ratios, age of vaginal opening or preputial separation, then ano-genital distance will be measured on postnatal day 4 for all F₂ pups.

13 POSTMORTEM:

13.1 TWO-GENERATION REPRODUCTION STUDY:

13.1.1 GROSS POSTMORTEM EXAMINATION:

13.1.1.1 Parental animals:

Complete macroscopic postmortem examinations will be performed on all adult animals, including animals euthanatized in a moribund condition or found dead. These evaluations will be performed under the direct supervision of a veterinary pathologist. The eyes of the parental animals will be examined *in situ* by gently pressing a moistened glass slide against the cornea and observing the eyes under fluorescent light. During the gross postmortem examination all abnormal observations will be recorded. The necropsy of the parental animals will include examination of the external surface and all orifices; the external surfaces of the brain and spinal cord; the organs and tissues of the cranial, thoracic, abdominal and pelvic cavities and neck; and the remainder of the carcass. Examination of all parental females which were exposed to males, will include a count of uterine implantation scars, if present.

13.1.1.2 Weanling Pups (F₁ and F₂):

At weaning (Day 25 - F₁ and Day 21 - F₂) one pup/sex/litter/group will be selected at random for a complete gross postmortem examination. These examinations will be performed under the supervision of a veterinary pathologist. To control for variation in body weight and organ weight, all pups will be sacrificed at the same age.

13.1.2 TIME OF NECROPSY:

13.1.2.1 Moribund Animals:

Animals showing signs of severe debility, particularly if death appears imminent, will be euthanatized to prevent loss of tissues through autolysis.

13.1.2.2 Terminal Necropsy Males (P_1 , P_2):

P_1 and P_2 males will be sacrificed after the last F_1 and F_2 litters, respectively, have been delivered. This will permit some evaluation of fertility (i.e., number of litters delivered) prior to sacrifice. The Sponsor will be notified and authorize the sacrifice of the P_1 and P_2 males.

13.1.2.3 Terminal Necropsy Females (P_1 , P_2):

All P_1 and P_2 females, regardless of reproductive status (unmated, mated but not pregnant, or retaining litters to weaning) will be sacrificed as a group after the last litters have weaned for all groups. Parental females (P_1 and P_2) will be necropsied on day 2 of diestrus whenever possible. This will be identified by daily vaginal smearing of the females for the occurrence of at least one estrous cycle after which time females found to be in day one of diestrus will be fasted overnight and necropsied the following day. The presence of diestrus will be confirmed by vaginal smearing the morning of necropsy.

13.1.2.4 Terminal Necropsy Pups (F_1 , F_2):

13.1.2.4.1 Dead and Culled Pups:

Pups found dead at birth or during the lactation period will be examined to the extent possible for defects and/or the cause of death and the presence or absence of milk in the stomach. Dead pups will not be eviscerated. Viscera will remain intact and the pup will be preserved in 10% neutral buffered formalin. Cannibalized pups will be examined to the extent possible and discarded. Culled pups will be examined for external irregularities, sexed internally to confirm external sexing and if unremarkable will be discarded. Culled pups with external irregularities will be preserved intact in 10% neutral buffered formalin.

13.1.2.4.2 Unselected F₁ Pups:

Pups selected as a pool of animals from which the P₂ parental animals will be selected but which were not identified to continue on study, will be given an external examination and if unremarkable, sacrificed and discarded. Pups with external findings will be given a gross internal examination and only abnormal tissues taken and preserved in 10% neutral buffered formalin. Remaining pups in each litter will be given a gross external examination at weaning (Day 25) and if unremarkable, sacrificed and discarded. Pups with external findings will be given a gross internal examination and only abnormal tissues taken and preserved in 10% neutral buffered formalin. Some control pups not selected into the pool of animals to become the P₂ parental generation will be used in a satellite study with vinyl chloride (see Study No. 96-408_).

13.1.2.4.3 Unselected F₂ Pups:

At weaning, unselected F₂ pups in each litter will be given a gross external examination and if unremarkable, sacrificed and discarded. Pups with external findings will be given a gross internal examination and only abnormal tissues taken and preserved in 10% neutral buffered formalin.

13.1.3 METHOD OF EUTHANASIA:

13.1.3.1 Parental Animals:

Exsanguination following anesthesia with inhaled carbon dioxide.

13.1.3.2 Weanlings:

Weanling pups selected for a complete gross postmortem examination will be sacrificed by exsanguination following anesthesia with inhaled carbon dioxide. Remaining pups will be sacrificed with an overdose of inhaled carbon dioxide.

13.1.3.3 Parental Animals:

The following organs will be weighed at terminal sacrifice from the first 15 P₁ and P₂ animals in each group:

uterus	ovaries
testes	right epididymis (total and cauda)
seminal vesicles (with coagulating glands and their fluids)	prostate
brain	liver
kidneys	lungs
adrenals	spleen
thymus	

Organ weight data will be presented as absolute values and relative to terminal body weight. Organ weights will not be recorded for animal dying spontaneously or sacrificed moribund.

13.1.3.4 Weanling Pups (F₁ and F₂):

The following organs will be weighed from the first 15 male and female pups per group selected for complete macroscopic examination at weaning:

ovaries	testes
brain	liver
kidneys	adrenals
spleen	thymus

Organ weight data will be presented as absolute values and relative to terminal body weight.

13.1.4 TISSUES PRESERVED:

13.1.4.1 Parental Animals:

Grossly abnormal tissues will be preserved for all parental animals. Tissues listed in Appendix A will be obtained at necropsy and preserved for all P₁ and P₂ parental animals.

13.1.4.2 Weanling Pups:

Grossly abnormal tissues and tissues listed in Appendix A will be preserved for all F₁ and F₂ weanling pups selected for complete gross macroscopic examination.

13.1.5 Preservatives:

All tissues - 10% neutral buffered formalin. Testes and epididymides of the parental animals will be fixed in Bouin's solution for at least 48 hrs prior to permanent storage in 10% neutral buffered formalin. Lungs will be infused with formalin to their approximate normal inspiratory volume. The nasal cavity will be flushed with formalin via the pharyngeal duct to ensure rapid fixation of the tissue.

13.1.6 MICROSCOPIC PATHOLOGY EVALUATIONS:

Slides of tissues listed in Appendix A (under Microscopic Examination) will be prepared and examined microscopically for all P₁ and P₂ animals in the control and high-dose groups. If microscopic findings indicative of an effect of test material administration are seen in high-dose animals, then examinations will be made of these tissues/organs for low- and mid-dose animals (additional cost). Additional examinations will be made only after consultation with the Sponsor and receipt of authorization from the Sponsor. Note: any abnormalities not noted during macroscopic postmortem examinations which are seen during histological processing will be recorded. Gross lesions will be examined at additional cost.

13.1.7 STAINS:

Standard stains used, hematoxylin and eosin. Special stains may be employed on selected tissues to aid in making a diagnosis at the discretion of the Study Pathologist. Special stains may be employed at the request of the Sponsor (additional cost).

13.1.8 SPERM COUNT, MOTILITY AND MORPHOLOGY ASSESSMENTS:

From the first 15 P₁ and P₂ parental males sacrificed at termination in each group, samples of sperm from the vas deferens (left) and distal cauda epididymis (left) will be collected. Motility will be assessed on sperm collected from the vas deferens and a count will be performed on the sperm sample collected from the cauda epididymis. A manual procedure developed in the Testing Facility will be used to assess motility and perform the count. Additionally, a slide of the sperm sample from the cauda epididymis will be prepared for morphological assessment if deemed necessary (Sponsor decision - additional cost item).

13.2 DEVELOPMENTAL TOXICITY STUDY:

13.2.1 MATERNAL TERM SACRIFICES:

Macroscopic postmortem examinations will be performed on all mated rats, including those dying spontaneously or killed in a moribund condition and on females sacrificed after aborting or premature delivery of a litter. The livers and kidneys will be weighed and preserved in 10% neutral buffered formalin for all females killed on Day 20 of gestation but microscopic examinations of these tissues will not be conducted unless deemed necessary to interpret other observations made during the study or as requested by the sponsor (additional cost item). Gross lesions identified during the macroscopic evaluations will be saved in 10% formalin. Dams showing signs of abortion or premature delivery (expulsion of concepti) will be killed (overdose of inhaled carbon dioxide) on the day such evidence is observed. Reproductive tracts will be examined and fetuses obtained 19 days or later will be given an external examination, eviscerated and processed for skeletal staining with Alizarin Red S. These fetuses will then be examined for skeletal malformations. Fetuses obtained earlier than Day 19 will be evaluated for external malformations and saved (10% neutral buffered formalin) at the discretion of the Study Director. Examination data for these fetuses (Day 19 of gestation or earlier) will not be analyzed with data for term Day 20 gestation fetuses. Data for these fetuses will be presented in a separate appendix to the final report.

13.2.2 Reproductive System:

The intact uteri (ovaries attached) will be removed from the abdominal cavity and weighed. This uterine weight data will then be used to calculate a corrected Day 20 gestation body weight for each animal. The corrected Day 20 gestation weight will be determined by

13.2.2 Reproductive System:

subtracting the gravid uterine weight from the terminal Day 20 gestation weight. Each uterine horn will then be evaluated for the number and location of the following:

- live fetuses (movement in response to touch);
- dead fetuses (lack of movement in response to touch but with no visible degeneration);
- late resorptions (recognizable dead fetus undergoing degeneration, regardless of size);
- early resorptions (evidence of implantation but no recognizable fetus);
- implantation sites (total of fetuses plus resorptions).

Ovaries: corpora lutea will be counted for each ovary.

Uteri without grossly visible implantations will be stained with ammonium sulfate (Salewski, 1964). If stained foci are present, the female will be considered pregnant for purposes of calculating pregnancy rates. The number of foci will not be used in the calculation of uterine implantation data.

13.2.3 Fetal evaluations:

13.2.3.1 External Evaluations:

All fetuses will be weighed and individually identified. Each fetus will be given a gross external examination for defects to include observation of the palate. The sex of each fetus will be noted by observation of the ano-genital distance.

13.2.3.2 Fetal Skeletal Evaluations:

Approximately one-half of the fetuses in each litter (alternating fetuses within the litter) will be processed for Alizarin Red S staining of the skeletal structures. Prior to processing, the intact fetuses will be killed (overdose of inhaled carbon dioxide) and eviscerated (internal sex noted). Following staining, these fetuses will be evaluated for skeletal malformations and ossification variations.

13.2.3.3 Fetal Soft Tissue Evaluations:

The remaining fetuses in each litter will be processed for soft tissue examination using a microdissection technique similar to the procedure of Staples (1974) . The evaluations will be performed on the fresh fetal specimens soon after removal from the uterus. The fetuses designated for soft tissue evaluation will be decapitated (head placed in Bouin's solution for later evaluation). The fetal specimens will then be secured beneath a dissecting microscope and dissected so as to permit evaluation of tissues in the thoracic, abdominal and pelvic cavities. At completion of the examination, the decapitated fetal specimens will be eviscerated and processed for Alizarin Red S staining. These fetuses will not be evaluated skeletally unless authorized by the sponsor (additional cost).

Fetal heads, preserved in Bouin's solution, will be sectioned with a razor blade. The serial, transverse sections generated during this procedure will be evaluated for malformations of the palate, eyes and brain.

Fetal soft tissue and skeletal evaluations (microdissection, stained specimens and head sections) will be performed under a dissecting microscope.

13.2.4 Resorptions:

Late resorptions will be examined externally for malformations. Malformation data for late resorptions will be reported but not included in the analyses of malformation data for live or dead fetuses recovered on Day 20 of gestation. Only late resorptions with external malformations will be saved (10% neutral buffered formalin) for future possible examination. Early resorption will be discarded.

14 PRESERVATION OF RECORDS AND SPECIMENS:

All data documenting experimental details and study procedures and observations will be recorded and maintained as raw data.

At the completion of the study, all reports, raw data, preserved specimens and retained samples will be maintained in the Testing Facility's Archives for a period of 10 years after submission of the signed final report.

The Sponsor will be contacted in order to determine the final disposition of these materials. The Sponsor is responsible for all costs associated with the storage of these materials beyond 10 years from the issuance of the final report

14 PRESERVATION OF RECORDS AND SPECIMENS:

and for any costs associated with the shipment of these materials to the Sponsor or to any other facility designated by the Sponsor.

15 STATISTICAL EVALUATIONS:

The following items will be analyzed statistically in the final report:

15.1 CONTINUOUS DATA:

15.1.1 Two-generation Reproduction Study:

Mean body weights (all recorded intervals - pre mating, gestation, lactation and post mating);

Mean body weight change;

-entire pre mating period (males and females) - entire pre mating period;
-over each weighing interval during the gestation and lactation periods to include Days 0-20 of gestation and Days 0-25 (F₁ litters) or Day 0-21 (F₂) of lactation;

-males during the post mating period (weekly and over the entire period).

Mean food consumption values;

-pre mating growth period (weekly);

-post mating period (weekly for males);

-gestation (Days 0-7, 7-14, 14-20);

-lactation (all recorded intervals);

Organ weight data (absolute and relative to the terminal body weight);

Mean pup weights (all recorded intervals during lactation);

Mean number of pups (live, dead, total) at birth (F₁ and F₂ litters);

Mean gestation length (F₁ and F₂ litters);

Mean pup live birth indices (F₁ and F₂ litters);

Mean pup viability indices (Days 0-4) and weaning indices (Days 4-25 or 21 for the F₁ and F₂ litters, respectively);

Mean age-to-criteria for vaginal opening and preputial separation (P₂ animals);

Mean sperm count and motility data.

15.1.2 Developmental Toxicity Study:

Mean maternal body weights (all recorded intervals during gestation) and weight gain (between all weighing intervals to include Days 6-20 of gestation using both the actual and corrected Day 20 gestation weight);

15.1.2 Developmental Toxicity Study:

Mean organ weight data, absolute and relative to the corrected Day 20 gestation weight;
Mean number of corpora lutea, implants, live and dead fetuses, resorptions per pregnant female;
Mean pre- and post-implantation loss indices;
Mean fetal weights (distinguished by sex and as a composite for both sexes);

15.1.3 STATISTICAL ANALYSES CONTINUOUS DATA - MULTIPLE GROUP ANALYSES:

Data will be compared between the sham, chamber-housed control and the treated groups.

Statistical evaluation of equality of means will be made by the appropriate one way analysis of variance technique, followed by a multiple comparison procedure if needed. Bartlett's test will be performed to determine if groups have equal variance. If the variances are equal ($p > 0.01$), parametric procedures will be used; if not ($p < 0.01$), non-parametric procedures will be used. The parametric procedures will be the standard one way ANOVA using the F distribution to assess significance. If significant differences among the means are indicated, Dunnett's test will be used to determine which means are significantly different from the control. If a nonparametric procedure for testing equality of means is needed, the Kruskal-Wallis test will be used, and if differences are indicated, a summed rank test (Dunn) will be used to determine which treatments differ from control.

A statistical test for trend in the dose levels will also be performed. In the parametric case (i.e., equal variance), standard regression techniques with a test for trend and lack of fit will be used. In the non-parametric case, Jonckheere's test for monotonic trend will be used.

The test for equal variance (Bartlett's) will be conducted at the 1% two-sided risk level. All other statistical tests will be conducted at the 5% and 1%, two-sided risk levels.

All ratios (pup survival indices, pre- and postimplantation loss indices) will be transformed via Bartlett's transformation followed by the arc-sine transformation prior to analysis. Data will be presented untransformed.

15.1.3 STATISTICAL ANALYSES CONTINUOUS DATA - MULTIPLE GROUP ANALYSES

References for these techniques are Snedecor, G.W., Cochran, W.G., *Statistical Methods*, 6th edition, Iowa State Univ. Press (1967); Hollander and Wolfe, *Nonparametric Statistical Methods*, John Wiley and Sons, New York (1973); Dunnett, C.W., *J. Am. Sta. Assn.* 50: 1096-1121 (1955) and *Biometrics* 20: 482 (1964).

Bartlett's Test	pp. 296-298	Snedecor & Cochran
ANOVA	pp. 277-279	Snedecor & Cochran
Dunnett's Test	pp. 1096-1121	Dunnett
	pp. 482-491	Biometrics
Kruskal-Wallis	pp. 114-116	Hollander & Wolfe
Summed Rank Test (Dunn)	p. 131	Hollander & Wolfe
Arc Sine Transformation	pp. 327-329	Snedecor & Cochran
Bartlett's transformation	p. 329	Snedecor & Cochran
Regression Analysis-Trend	pp. 135-153	Snedecor & Cochran
Lack of fit	pp. 456-459	Snedecor & Cochran
Jonckheere's Statistic	pp. 120-123	Hollander & Wolfe

15.2 INCIDENCE DATA:

15.2.1 Two-generation Reproduction Study:

Mortality rates;
Mating indices (male and female);
Pregnancy rates;
Male fertility indices;
Litter survival indices;

15.2.2 Developmental Toxicity Study:

Maternal Mortality
Pregnancy rates
Incidence of females with resorptions;
Incidence of fetuses with malformations/variations - external, soft tissue and skeletal examinations;
Incidence of litters containing fetuses with malformations/variations - external, soft-tissue and skeletal.

15.2.3 INCIDENCE DATA ANALYSIS:

Data will be compared between the sham, chamber-housed control and the treated groups.

Statistical analysis of incidence data will be performed using contingency tables. First, a standard Chi-square analysis will be performed to determine if the proportion of incidences differed between the groups tested. Next, each treatment group will be compared to the control group using a 2 x 2 Fisher Exact Test; the significance level will be corrected via the Bonferroni inequality to assure an overall test of the stated significance level. Thirdly, Armitage's test for linear trend in the dosage groups will be performed. In keeping with standard statistical practice, if any one cell has an expected value less than 5, the Chi-square and Armitage's tests will not be reported. When this occurs, only the Fisher Exact test (corrected via Bonferroni inequality) will be performed and reported.

All tests will be reported at the 5% and 1% level of significance.

References for the techniques are Snedecor, G.W., and Cochran, W.G., *Statistical methods*, 6th ed., Iowa State University Press, Ames, Iowa (1971); Bradley, J.V., *Distribution Free Statistical Tests*, Prentice-Hall, Englewood Cliffs, New Jersey (1968); Miller, R.G., Jr., *Simultaneous Statistical Inference*, McGraw-Hill Book Co., New York (1966); Armitage, P., "Tests for Linear Trends in Proportions and Frequencies", *Biometrics*, (Sept. 1955).

Chi-square	pp. 250-253	Snedecor & Cochran
Fisher Exact Test	pp. 195-203	Bradley
Bonferroni Inequality	p. 15	Miller
Armitage's Test	pp. 375-386	Armitage

16 REFERENCES:

ATSDR, (1993). Toxicology Profile for Vinyl Chloride. U.S. Department of Health and Human Services. Public Health Services. Agency for Toxic Substances and Disease Registry.

EEC (1988). European Economic Community. Methods for the Determination of Toxicity. Official Journal of the European Communities, Vol.31, No.. L133, 30 May 1988. ISSN 0378-6978.

EPA (1985). Environmental Protection Agency Toxic Substances Control Act Test Guidelines, Final Rule. 40 CFR Part 798, 27 September 1985, pp. 39426-39433.

16 REFERENCES:

- EPA (1990). Environmental Protection Agency Toxic Substances Control Act; Good Laboratory Practice Standards. 40 CFR Part 792 (1 July 1990).
- FDA (1988). Food and Drug Administration Good Laboratory Practice for Nonclinical Studies. 21 CFR Part 58 (1 April 1988).
- OECD (1981). Organisation for Economic Co-Operation and Development Guidelines for Testing of Chemicals, Section 4 - Health Effects, Paris.
- OECD (1982). Organisation for Economic Co-Operation and Development, Principles of Good Laboratory Practice, ISBN 92-64-12367-9, Paris.
- Plowchalk, D.R., Smith, B.J. and Mattison, D.R. (1993). Assessment of toxicity of the ovary using follicle quantitation and morphometrics. In Methods in Toxicology, Vol.3, Part B, Female Reproductive Toxicology. (J. J. Heindel and R.E. Chapin, Eds.). Academic Press, Inc., New York, NY.
- Salewski, E. (1964). Farbemethode zum makroskopischen nachweis von implantationsstellen am uterus der ratte. *Archiv. Path. Exp. Pharmacol.*, 247:367
- Staples, R. E. (1974). Detection of Visceral Alterations in Mammalian Fetuses. *Teratology*, 9:37 (Abstract).

17 REPORT:

17.1 STATUS REPORT:

For the two-generation reproduction study, status reports will be issued monthly during the premating treatment period and after weaning of the F₁ and F₂ litters. In the developmental toxicity study a status report will be submitted after the last Day 20 gestation maternal sacrifices. These reports will include:

Two-generation Reproduction Study:

Mortality rates
Mean weekly body weight and weight gain data;
Mean weekly food consumption premating period;
Summary of detailed physical examinations;
Mating indices (males and females);
Male fertility indices;
Pregnancy rates;
Gestation length;

17.1 STATUS REPORT:

Number of pups at birth (live, dead and total) and number of live pups surviving during lactation;
Mean pup weights (lactation);
Individual female litter data (F_1 , F_2);
Maternal gestation body weights and weight gains;
Maternal food consumption - gestation/lactation;
Summary of gross postmortem evaluations (adults, weanlings)

Developmental Toxicity Study:

Mortality rates:

Mean body weight and weight gain data during gestation;
Mean food consumption data;
Summary of detailed physical examination data;
Mean corpora lutea and uterine implantation data;
Mean number of live and dead fetuses and resorptions per pregnant female;
Mean pre- and post-implantation loss indices;
Incidence of females with resorptions;
Mean fetal weights;
Fetal external examination data;
Individual maternal Day 20 gestation sacrifice data;
Maternal organ weight data;
Summary of maternal gross postmortem examination data.

17.2 FINAL REPORT:

One copy of a draft report will be submitted following termination of the study. After receipt and review of the Sponsor's comments, appropriate changes will be made and two copies of a signed, final report will be issued. (Additional copies will be provided at additional cost). The report will include but not be limited to the following:

17.2.1 General:

Compliance Statement;
Abstract;
Introduction;
Experimental Design;
Materials and Methods;
Discussion of study results;
Conclusion and No Observed Effect Level (NOEL) statement, if applicable;
Inhalation Exposure Report;
References for experimental methodology;
Senior personnel participating in the study;

17.2.1 General:

Quality Assurance Statement.

17.2.2 Data tabulations for parental generations (P_1 , P_2):

Mortality - termination history;
Physical in-life observations (summarized and individual data presented monthly throughout the study);
Mating indices;
Pregnancy rates;
Male fertility indices;
Mean body weight data (all interval);
Mean food consumption data (all intervals);
Mean weight gain data (premating, postmating [males], gestation and lactation intervals);
Statement on estrous cycle data;
Macroscopic postmortem observations (adults, weanlings);
Microscopic pathology examinations;
Organ weight data;
Sperm assessment data.

17.2.3 Data tabulations for litters and offspring (F_1 and F_2):

Mean gestation length;
Mean number of pups (live, dead and total) at birth and live pups at Days 4, 7, 14 and weaning (Day 25 - F_1 and Day 21 - F_2);
Litter survival indices;
Pup live birth index;
Pup viability and weaning indices;
Mean pup weights (all recorded intervals during lactation);
Pup sex ratio at birth, Day 4 (pre- and postcull) and weaning;
Pup gross postmortem observations;
Individual female litter data.

17.2.4 Data tabulation for the developmental toxicity study:

Maternal mortality
Maternal body weight and weight gain data;
Maternal food consumption;
Physical observation data:
Pregnancy rates;
Mean number of corpora lutea and uterine implantations;
Mean number of live and dead fetuses;
Mean pre- and post-implantation loss indices;
Mean number of resorptions;
Incidence of females with resorptions;

17.2.4 Data tabulation for the developmental toxicity study:

Types of findings and incidence of fetuses with external, soft tissue and skeletal malformations/variatioins;
Incidence of litters containing fetuses with malformations/variatioins (external, soft tissue and skeletal)
Mean fetal weights;
Fetal sex distribution ratios;

17.2.5 Appendices:

All individual animal data (adults, pups, weanlings and fetuses) including but not limited to the following will be presented in the appendices: body weight and weight gain, food consumption, physical observation data, litter and uterine implantation data, organ weight data, sperm assessment data, estrous cycle data, gross postmortem findings, microscopic examination data, chamber exposure data.


18 SIGNATURES:

18.1 INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC):

The IACUC Protocol Review Subcommittee has reviewed this protocol and found it to be in compliance with all appropriate regulations.


BY:  DATE: 11 Oct 96

TITLE: Institutional Animal Care and Use Committee Member
FOR: Huntingdon Life Sciences
Institutional Animal Care and Use Committee


BY:  DATE: 11 Oct 96

TITLE: Institutional Animal Care and Use Committee Member
FOR: Huntingdon Life Sciences
Institutional Animal Care and Use Committee

18.2 PROTOCOL REVIEWED AND ACCEPTED:

BY:  DATE: 25 Oct 96

Raymond E. Schroeder, M.S., DABT
TITLE: Study Director
FOR: Huntingdon Life Sciences

BY:  DATE: 10/16/96

Robert A. Venezia, Ph.D.
TITLE: Sponsor Representative
FOR: Chemical Manufacturers Association
Chemstar Department

APPENDIX A
Tissues Preserved/Examined Microscopically

No. *	Tissue	Preserved	Microscopic Examination (Groups)	
			I, IV	II, III
2	adrenals	X		
1	aorta	X		
1	auditory sebaceous glands	X		
1	bone (including joint)	X		
3	brain (cerebrum, brainstem, cerebellum)	X		
1	cecum	X		
2	coagulating glands	X	X	
1	colon	X		
1	duodenum	X		
2	epididymis	X	X	
1	esophagus	X		
2	eyes	X		
1	heart	X		
1	ileum	X		
1	jejunum	X		
2	kidneys	X	X	
2	lacrimal/Hardarian glands	X		
1	larynx	X		
2	liver	X	X	
2	lungs	X	X	
1	mammary glands	X	X	
1	mediastinal lymph nodes	X		
1	mediastinal tissues	X		
1	mesenteric lymph nodes	X		

APPENDIX A
Tissues Preserved/Examined Microscopically

No. *	Tissue	Preserved	Microscopic Examination (Groups)	
			I, IV	II, III
1	mesenteric tissues	X		
4	nasal tissues (turbinates)	X	X	
1	oral tissues	X		
1	ovary ^b	X	X	
2	oviducts	X	X	
1	pancreas	X		
2	parathyroid glands	X		
1	peripheral nerve	X		
1	pituitary	X	X	
1	prostate	X	X	
1	rectum	X		
2	salivary glands	X		
2	seminal vesicles	X	X	
1	skeletal muscle	X		
1	skin	X		
3	spinal cord (cervical, thoracic, lumbar)	X		
1	spleen	X		
1	stomach	X		
2	testis	X	X	
1	thymus	X		
2	thyroid gland	X		
1	tongue	X		
1	trachea	X	X	
1	urinary bladder	X		

APPENDIX A
Tissues Preserved/Examined Microscopically

No. ^a	Tissue	Preserved	Microscopic Examination (Groups)	
			I, IV	II, III
2	uterus (body/horns with cervix)	X	X	
1	vagina	X	X	
	gross lesions	X	X	

^a Number of organs/sections preserved/examined.

^b Only the right ovary will be routinely processed for microscopic evaluation. The left ovary will be saved for possible oocyte quantification. If deemed necessary by the Sponsor (additional cost), oocyte quantification will include evaluation of a minimum of 10 sections randomly selected from one completely sectioned ovary per female of the high-dose and control groups. Ovarian follicles will be placed into one of three categories as described by Plowchalk et al., (1993). The total number of follicles and the number of follicles in each of the three categories will be evaluated. Ovaries from the low- and mid-dose groups may be evaluated if treatment-related changes are observed in the high-dose group.

APPENDIX B

TEST MATERIAL PROPERTIES

Chemical name	Vinyl chloride
Synonyms	Monochloroethylene, VC, VCM, vinyl chloride monomer
Molecular formula	C_2H_3Cl
Molecular weight	62.5
Structures	$CH_2=CHCl$
Appearance	Colorless gas
Vapor pressure	2,530 mm Hg at 20 degrees C
Saturated atmosphere	Gas at room temperature
Vapor density	2.16
Flash point	-77.75 degrees C (open cup)
Boiling point	-13.6 degrees C
Specific gravity	0.9121
Conversion factors	1 mg/m ³ = 0.39 ppm in air 1 ppm = 2.60 mg/m ³ in air

Appendix A

CURRICULUM VITAE

NAME: Paul E. Newton, Ph.D.
Diplomate, American Board of Toxicology

PRESENT POSITION: Project Manager
(since November 1995) Huntingdon Life Sciences Inc.
East Millstone, NJ 08875-2360

Responsible for all aspects of conducting toxicity studies following GLPs including protocol design, development of test exposure/dose and monitoring systems, evaluation of data, preparation of final reports and client/auditor interface.

EDUCATION:

1979 The Medical College of Wisconsin
Ph.D. Respiratory Physiology
Dissertation: "Control of Human Ventilation
During CO₂ Breathing"

1968-1970 Kansas State University
Engineering (Graduate courses in Convective Heat and
Mass Transfer, Boundary Layer Theory, Radiation Heat
Transfer, Fluid Mechanics, Thermodynamics, Control
Theory, Engineering Analysis, Analog Computer and
Statistics)

1968 Rose Polytechnic Institute
M.S. Biological Engineering

1967 Rose Polytechnic Institute
B.S. Mathematics

PROFESSIONAL EXPERIENCE:

1986 - 1995 Director of Inhalation Toxicology
Pharmaco LSR Inc., Toxicology Services Worldwide
East Millstone, NJ 08875

Responsible for the Department of Inhalation Toxicology, overseeing the activities of the technical staff. As a Study Director, responsible for all aspects of the conduct of inhalation studies. Responsibilities include protocol design, development of test exposure and monitoring systems, evaluation of data, preparation of final reports and client/auditor interface.

Paul E. Newton, Ph.D.

PROFESSIONAL EXPERIENCE-continued:

1985 - 1986 American Biogenics Corporation
 Decatur, Illinois
 Director, Inhalation Toxicology

Director of Inhalation Toxicology and responsible for overall operation of inhalation toxicology facility. This included client-sponsored acute, subchronic and chronic studies of vapors and liquid or dust aerosols as well as pyrolysis testing following NBS guidelines.

1979 - 1985 University of California, Irvine
 Toxic Hazards Research Unit, Wright-Patterson AFB, OH
 Head, Respiratory Toxicology Department

Responsible for design, implementation and operation of a pulmonary toxicology program including preparation of budgets, protocols and standard operating procedures, management of personnel, equipment specification and computer software development for high speed data acquisition and processing using GLP techniques. Research involved evaluation of pulmonary dynamics, gas exchange, distribution, pulmonary defense mechanisms, and the toxicodynamics and toxicokinetics of various chemical agents on rats, mice and dogs. Compounds studied included: ozone, carbon dioxide, propylene glycol dinitrate, jet fuels JP-8 and shale JP-4, papain, bleomycin, 4-ipomeanol and o-ethyl-o-(2-diisopropylamino-ethyl) methylphosphonite.

1971 - 1979 The Medical College of Wisconsin
 Department of Environmental Medicine
 Senior Bioengineer

Responsible for specification of instrumentation systems, writing computer programs and the collection, processing and statistical analysis of all pulmonary, cardiovascular, neurological and behavioral test data investigated during human inhalation toxicological experiments. Compounds included: carbon monoxide, methylene chloride, trichloroethylene, 1,1,1-trichloro-ethane, tetrachloroethylene, acetone, toluene, xylene, ethyl alcohol, fluorocarbon-11, fluorocarbon-12, isobutane, propane, propylene glycol dinitrate, methyl chloride, Halon 1211, Halon 2402 and Halon 1301.

PROFESSIONAL ACCREDITATION:

Diplomate, American Board of Toxicology, 1984
Recertified in 1989 and 1993

CERTIFICATES/AWARDS:

Best Poster Presentation, Mid-Atlantic Soc. of Toxicol. (1992)
Distinguished Service Award (1976-79) Milwaukee Fire
Department

Paul E. Newton, Ph.D.,

PROFESSIONAL MEMBERSHIPS:

Society of Toxicology, Mid-Atlantic and Midwest Regional
Society of Toxicology
American College of Toxicology
American Association of Pharmaceutical Scientists
American Association Aerosol Research
American Thoracic Society
Association of Inhalation Toxicologists
European Society of Toxicology
International Society of Aerosols in Medicine

PUBLICATIONS (Book Chapters):

Stewart, R.D., Hake, C.L., Lebrun, A.J., Kalbfleisch, J.H., Newton, P.E., Peterson, J.E., Cohen, H.H., Struble, R. and Busch, K.A. 1974. "Effects of Trichloroethylene on Behavioral Performance Capabilities", *Behavioral Toxicology*. Xintaras, C., Johnson, B.L. and deGroot, L, Eds. p. 96-129. NIOSH, Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402

Stewart, R.D., Hake, C.L., Peterson, J.E., Forster, H.V., Newton, P.E., Soto, R.J. and Lebrun A.J. 1974. "Development of Biological Standard for Trichloroethylene", *op. cit.*, p. 81-91.

Stewart, R.D., Newton, P.E., Hosko, M.J., Peterson, J.E. and Mellender, J.W. 1975. "The Effect of Carbon Monoxide on Time Perception, Manual Coordination, Inspection and Arithmetic", *Behavioral Toxicology*, Edited by Weiss & Laties, Chap. 2, p. 29-60. Plenum Press, New York

Stewart, R.D., Herrmann, A.A., Baretta, E.D., Forster, H.V., Crespo, J.H., Newton, P.E. and Soto, R.J. 1981. "Human Exposure to Aerosol Propellants", *Aerosol, Airways and Asthma*. Trautlein, J.J., Ed. Spectrum Publ., Jamaica, New York

Newton, Paul E. 1995. "Inhalation Toxicology", *CRC Handbook of Toxicology*, Edited by Derelanko, M.J. and Hollinger, M.A., Chap. 5, CRC Press, Boca Raton, FL

JOURNAL ARTICLES:

Newton, P.E. 1971. "The Effects of Sound on Plant Growth", *J. Aud. Eng. Soc.*, 19 (3): 202-205

Stewart, R.D., Newton, P.E., Hosko, M.J. and Peterson, J.E. 1973. "Effects of Carbon Monoxide on Time Perception", *Arch. Env. Health*, 27: 155-160

Stewart, R.D., Peterson, J.E., Newton, P.E., Hake, C.L., Hosko, M.J., Lebrun, A.J. and Lawton, G.M. 1974. "Experimental Human Exposure to Propylene Glycol Dinitrate", *Toxicol. Appl. Pharmacol.* 30: 377-395

Paul E. Newton, Ph.D.

JOURNAL ARTICLES - continued:

Stewart, R.D., Herrmann, A.A., Baretta, E.D., Sikora, J.J., Newton, P.E. and Soto, R.J. 1977. "Acute and Repetitive Human Exposure to Isobutane", *Scand. J. Work, Environ. & Health* 3: 234-243

Stewart, R.D., Newton, P.E., Baretta, E.D., Herrmann, A.A., Forster, H.V. and Soto, R.J. 1978. "Physiological Response to Aerosol Propellants", *Environmental Health Perspectives*, 26: 275-285

Erk, S.D., Jarboe, C.H., Newton, P.E. and Pfledderer, C. 1982. "Gas Chromatographic Determination of 1, 2-Propanediol Dinitrate in Blood", *Journal of Chromatographic Science*, 240: 117-123

Newton, P.E., Hamilton, L.H. and Forster, H.V. 1983. "Measurement of Ventilation using Digitally Filtered Transthoracic Impedance", *J. Appl. Physiol.: Respirat. Environ. Exercise Physiol.* 54: 1161-1166

Newton, P.E., Latendresse, J.R., Mattie, D. and Pfledderer, C. 1985. "Alterations in Alveolar Clearance after 4-Isoprene Induced Necrosis of Clara Cell and Ciliated Cells in the Terminal Bronchiole of the Rat", *Toxicol. Appl. Pharm.* 80: 534-541

Newton, P.E. and Pfledderer, C. 1986. "Deposition and Clearance of Radio-labeled Particles Inhaled during CO₂ Exposures", *J. Appl. Toxicology*, 6: 113-119

Newton, P.E., Becker, S.V. and Hixon, C.J. 1991. "Pulmonary Function and Particle Deposition and Clearance in Rats after a 90-Day Exposure to Shale Oil Derived Jet Fuel JP-4", *Inhalation Toxicology* 3: 195-210

Hoffman, G.M., Newton, P.E., Thomas, W.C., Birnbaum, H.A. and Kennedy, Jr., G.L. 1991. "Acute Inhalation Toxicity Studies in Several Animal Species of an Ethylene Oxide/Propylene Oxide Copolymer (UCON 50-HB-5100)", *Drug and Chemical Toxicology* 14: 243-256

Nair, R.S., Johannsen, F.R., Bolte, H.F., Newton, P.E. and Rinehart, W.E. 1992. "Toxicity of Calcium Sodium Metaphosphate Fiber, II. Chronic Inhalation and Oncogenicity Study", *Fundamental and Applied Toxicology* 19: 79-90

Newton, P.E., Schroeder, R.E., Sullivan, J.B., Busey, W.M., and Banas, D.A. 1993. "Inhalation Toxicity of Phosphine in the Rat: Acute, Subchronic and Developmental", *Inhalation Toxicology*, 5 (2): 233-239

Paul E. Newton, Ph.D.

JOURNAL ARTICLES - continued:

Newton, P.E., Bolte, H.F., Daly, I.W., Pillsbury, B.D., Ben-Dyke, R., Drew, R.T. and Sheldon, A.W. 1994. "Subchronic and Chronic Inhalation Toxicity Studies of Antimony Trioxide in the Rat", *Fundamental and Applied Toxicology* 22, 561-576

POSTERS AND CONFERENCE PROCEEDINGS:

Stewart, R.D., Fisher, T.N., Peterson, J.E., Hosko, M.J., Baretta, E.D., Dodd, H.C., Newton, P.E. and Herrmann, A.A. 1970. "Experimental Human Exposure to Carbon Monoxide", *Proc. of First Annual Conference on Environmental Toxicology*, AMRL-TR-70-102, Aerospace Medical Research Laboratory, Wright-Patterson Air Force Base, Ohio

Newton, P.E., Forster, H.V. and Klein, J.P. 1977. "Ventilation, PaCO₂ and Arterial pH in Man while Breathing 1 and 2% CO₂", *Fed. Proc.*, 36 (3): 446

Forster, H.V., Klein, J.P., Newton, P.E. and Hamilton, L. 1979. "Effect of Increased FICO₂ on Oxygen Consumption (Vo₂), CO₂ Storage" (CCO₂), *Fed. Proc.* 38: 1034

Klein, J.P., Forster, H.V., Newton, P.E. and Kampine, J.P. 1979. "Can Humans Maintain PaCO₂ Homeostases as FICO₂ is Increased?", *Fed. Proc.*, 38: 1033

Stewart, R.D., Newton, P.E., Wu, A., and Stewart, T.A. 1979. "The Milwaukee Program for Detecting Carboxyhemoglobin Levels in Firefighters Fifth Symposium on the Occupational Health and Hazards of the Fire Service", San Diego, International Association of Firefighters, Washington, D.C.

Newton, P.E. 1980. "Elevated Carboxyhemoglobins in Fire Fighters", *Proc. of Tenth Annual Conference on Environmental Toxicology*, AMRL-TR-79-121, Aerospace Medical Research Laboratory, Wright-Patterson Air Force Base, Ohio

Newton, P.E., Forster, H.V., Hamilton, L. and Christman, N.T. 1980. "Ventilation Measurements made using Digitally Filtered Transthoracic Impedance", *Fed. Proc.* 39: 576

Newton, P.E., Erk, S.D. and Pfledderer, C. 1981. "Hypotensive Effect of Tween 80 in Dogs", *Physiologist*, 24: 14

Paul E. Newton, Ph.D.

ABSTRACTS, CONFERENCE PROCEEDINGS - continued:

Newton, P.E., Pfledderer, C. and Erk, S.D. 1982. "Long and Short Term Pulmonary Clearance in Rats after Exposure to Ozone", Abstracts of Papers, A.I.H.A. Meeting, Cincinnati, OH.

Newton, P.E., Latendresse, J.R., Mattie, D.R. and Pfledderer, C. 1985. "Alterations in Alveolar Clearance after 4-ipomeanol Induced Necrosis of Clara and Ciliated Cells in the Terminal Brochiole of the Rat", *The Toxicologist* 5: 932

Hoffman, G.M., Newton, P.E., Thomas, W.C. and Kennedy, G.L. 1990. "Multi-Species Acute Inhalation Toxicity Study of an EO/PO Copolymer (UCON-50-HB-5100)", *Toxicologist* 10: 807

Newton, P.E., Bolte, H.F. and Sheldon, A.W. 1990. "Pulmonary Toxicity after Chronic Inhalation Exposure to Antimony Trioxide (Sb_2O_3) in Rats", *The Toxicologist* 10: 624

Newton, P.E., Bolte, H.F. and Sheldon, A.W. 1990. "Pulmonary Toxicity after Chronic Inhalation Exposure to Antimony Trioxide (Sb_2O_3) in Rats", *J. Aerosol Medicine* 3: 78

Newton, P.E., Sullivan, J.B., Busey, W.M. and Banas, D.A. 1991. "Acute and Subchronic Inhalation Toxicity of Phosphine", *The Toxicologist* 11: 210

Duffy, J., Newton, P.E., Cockrell, B., Soiefer, A., Kirwin, C. and Daughtrey, W. 1991. "A Thirteen Week Inhalation Toxicity Study of Commercial Hexane in the Rat and Mouse", *The Toxicologist* 11: 1219

Nair, R.S., Johannsen, F.R., Bolte, H.F., Newton, P.E. and Rinehart, W.E. 1991. "Chronic Inhalation and Oncogenicity Study with Calcium Sodium Metaphosphate (CSM) Fiber", *The Toxicologist* 11: 255

Newton, P.E., Lake, L.K., Bolte, H.F. and Osimitz, T.G. 1992. "A Subchronic (4-Week) Inhalation Toxicity Study of a High Molecular Weight Emulsion Polymer in the Rat", *The Toxicologist* 12: 828

Schroeder, R.E., Newton, P.E., Sullivan, J.B. and Busey, W.M. 1992. "An Inhalation Developmental Toxicity Study of Phosphine in Rats", *The Toxicologist* 12: 401

Knaak, J.B., Barfknecht, T.R., Smith, L.W. and Newton, P.E. 1994. "Subchronic Inhalation Toxicity Study of p-Chlorobenzoatrilfluoride (PCBTF) in the Rat via Whole-Body Exposures", *The Toxicologist* 14, No. 1213

Paul E. Newton, Ph.D.

ABSTRACTS, CONFERENCE PROCEEDINGS - continued:

Newton, P.E., Wooding, W.L. and Rinehart, W.E. 1994. "An Inhalation Oncogenicity Study in Mice of Methylethylketoxime", *The Toxicologist* 14: No. 1220

Duffy, J.S., Haddock, L.S., Daughtrey, W.D., Keenan, T.H. and Newton, P.E. 1994. "Chronic Inhalation Study of Commercial Hexane in Rats", *The Toxicologist* 14: No. 1233

Hoffman, G.M., Newton, P.E. and Thomas W.C. 1994. "Inhalation Toxicology Testing Methods of Fiber Finishes", American Fiber Manufacturers' Association Conference

Knaak J.B., Smith, L.W. and Newton, P.E. 1995. "Subchronic (90-Day) Inhalation Toxicity and Neurobehavioral Study of PCBTF in the Rat", *The Toxicologist*, Vol. 15, No. 444

Newton, P.E., Wooding, W.L. and Rinehart, W.E. 1995. "An Inhalation Oncogenicity Study in Rats of Methylethylketoxime", *The Toxicologist*, Vol. 15, No. 978

TECHNICAL REPORTS:

Stewart, R.D., Barenta, E.D., Dodd, H.C., Donohoo, K., Graff, S., Kalbfleisch, J., Newton, P.E., Platte, L., Rimm, A., Stewart, E. and VanYserloo, B. National Carboxyhemoglobin Survey, CO-COHb Symposium, Washington, D.C., March 1973.

Stewart, R.D., Hake, C.L., Lebrun, A.J., Kalbfleisch, J.H., Newton, P.E., Peterson, J.E., Cohen, H.H., Struble, R. and Busch, K.A. "Effects of Trichloroethylene on Behavioral Performance Capabilities", NIOSH Report #NIOSH-MCOW-ENVM-PCE-74-6, National Institute for Occupational Safety and Health, Cincinnati, OH (1974).

Stewart, R.D., Hake, C.L., Forster, H.V., Lebrun, A.J., Peterson, J.E., Wu, A. and Staff; "Tetrachloroethylene: Development of a Biologic Standard for the Industrial Worker by Breath Analysis", NIOSH Report #NIOSH-MCOW-ENVM-PCE-74-6, National Institute for Occupational Safety and Health, Cincinnati, OH (1974).

Stewart, R.D., Hake, C.L., Forster, H.V., Lebrun, A.J., Peterson, J.E., Wu, A. and Staff; "Trichloroethylene: Development of a Biologic Standard for the Industrial Worker by Breath Analysis", NIOSH Report #NIOSH-MCOW-ENVM-PCE-74-8, National Institute for Occupational Safety and Health, Cincinnati, OH (1974).

Stewart, R.D., Hake, C.L., Forster, H.V., Lebrun, A.J., Peterson, J.E., Wu, A. and Staff; "Methylene Chloride: Development of a Biologic Standard for the Industrial Worker by Breath Analysis", NIOSH Report #NIOSH-MCOW-ENVM-PCE-74-9, National Institute for Occupational Safety and Health, Cincinnati, OH (1974).

Paul E. Newton, Ph.D.

TECHNICAL REPORTS:

Stewart, R.D., Hake, C.L., Wu, A., Graff, S.A., Forster, H.V., Lebrun, A.J., Newton, P.E. and Soto, R.J.; "1,1,1-Trichloro-ethane: Development of a Biologic Standard for the Industrial Worker by Breath Analysis", NIOSH Report #NIOSH-MCOW-ENVM-1,1,1-T-75-4, National Institute for Occupational Safety and Health, Cincinnati, OH (1975).

Stewart, R.D., Hake, C.L., Forster, H.V., Lebrun, A.J., Peterson, J.E., Wu, A., and Staff; "Toluene: Development of a Biologic Standard for the Industrial Worker by Breath Analysis", NIOSH Report #NIOSH-MCOW-ENVM-MC-75-3, National Institute for Occupational Safety and Health, Cincinnati, OH (1975).

Stewart, R.D., Hake, C.L., Wu, A., Graff, S.A., Forster, H.V., Keeler, W.H., Lebrun, A.J., Peterson, J.E., Newton, P.E. and Soto, R.J.; "Acetone: Development of a Biologic Standard for the Industrial Worker by Breath Analysis", NIOSH Report #NIOSH-MCOW-ENVM-A-75-5, National Institute for Occupational Safety and Health, Cincinnati, OH (1975).

Stewart, R.D., Hake, C.L., Wu, A., Graff, S.A., Forster, H.V., Keeler, W.H., Lebrun, A.J., Peterson, J.E., Newton, P.E. and Soto, R.J.; "Methyl Chloride: Development of a Biologic Standard for the Industrial Worker by Breath Analysis", NIOSH Report #NIOSH-MCOW-ENVM-MCM-77-1, National Institute for Occupational Safety and Health, Cincinnati, OH (1977).

Stewart, R.D., Hake, C.L., Wu, A., Graff, S.A., Forster, H.V., Keeler, W.H., Lebrun, A.J., Peterson, J.E., Newton, P.E. and Soto, R.J.; "Styrene: Development of a Biologic Standard for the Industrial Worker by Breath Analysis", NIOSH Report #NIOSH-MCOW-ENVM-STY-77-2, National Institute for Occupational Safety and Health, Cincinnati, OH (1977).

Stewart, R.D., Hake, C.L., Wu, A., Kalbfleisch, J., Newton, P.E., Marlow, S.K. and VICEVIC-Salama, M.; "Effects of Perchloro-ethylene/Drug Interaction on Behavior and Neurological Function", U.S. Department of Health, Education and Welfare, Public Health Service, Center for Disease Control, National Institute for Occupational Safety and Health, Division of Biomedical and Behavioral Science, Publication #77-191, April 1977.

Stewart, R.D., Herrmann, A.A., Baretta, E.D., Forster, H.V., Crespo, J.H., Newton, P.E. and Soto, R.J.; "Acute and Repetitive Human Exposure to Difluorodichloromethane", Report #PB279204/LLC, U.S. Department of Commerce, The National Technical Information Service, Springfield, VA (1978).

Paul E. Newton, Ph.D.

TECHNICAL REPORTS - continued:

Stewart, R.D., Newton, P.E., Baretta, E.D., Herrmann, A.A., Forster, H.V., Sekora, J.J. and Soto, R.J.; "Acute and Repetitive Human Exposure to Fluorordichloromethane", Report #PB279203/LLC, U.S. Department of Commerce, The National Technical Information Service, Springfield, VA (1978).

Stewart, R.D., Hermann, A.A., Baretta, E.D., Forster, H.V., Crespo, J.H., Newton, P.E. and Soto, R.J.; "Acute and Repetitive Human Exposure to Isobutane and Propane", Report #PB279205/LLC, U.S. Department of Commerce, The National Technical Information Service, Springfield, VA (1978).

Stewart, R.D., Newton, P.E., Wu, A., Kalbfleisch, J.H. and Stewart, T.A.; "Carboxyhemoglobin Trend in St. Louis Blood Donors, 1971-1975", Report #CRC-AORAC-CAPM-8-68/MCOW-ENVM-CO-78-1, The Coordinating Research council, Inc., New York, NY (1978).

Stewart, R.D., Newton, P.E., Kaufman, J., Forster, H.V., Klein, J.P., Keelen, M.H., Stewart, D.J., Wu, A. and Hake, C.L.; "The Effect of a Rapid 4% Saturation Increase in Carboxyhemoglobin on Maximal Treadmill Exercise," Report #CRC-APRAC-CAPM-22-75/MCOW-ENVM-CO-78-2, The Coordinating Research Council, Inc., New York, NY (1978).

Stewart, R.D., Newton, P.E., Wu, A., Hake, C.L. and Krivanek, N.D.; "Human Exposure to Halon 1301", E.I. DuPont de Nemours & Co., Inc., Wilmington, DE (1978).

Erk, S.D., Newton, P.E., MacEwen, J.D. and Vernot, E.H.; "Evaluation of the Toxicokinetic Study of 1,2-propanediol Dinitrate (PGDN) in the Dog", AFAMRL-TR-82-27, Wright-Patterson Air Force Base, OH.

Horton, J.R., Gaworski, C.L., Newton, P.E. et al. "Evaluation of the Acute Toxicity, Irritation, Sensitization and Subchronic Dermal Toxicity of Antimony Thioantimonate Lubricant", NTIS/AD-A166 873/9 (1986).

REPORTS ON PROPRIETARY COMPOUNDS SUBMITTED TO SPONSORS:

Approximately 500 confidential reports on acute, sub-chronic, chronic, and reproduction/teratology inhalation studies in rodents and higher animal species. These reports were issued to the pharmaceutical, agricultural and industrial chemical, food additive and cosmetic industries.

I certify that the above is a true and accurate account of my professional career.

Signed: _____

Date: _____

CMA 118490

CURRICULUM VITAE

NAME: Henry F. Bohte, D.V.M., Ph.D.

PRESENT POSITION: Senior Staff Pathologist
Huntingdon Life Sciences
East Millstone, NJ 08875

Performs the duties of a pathologist. Conducts macroscopic and microscopic examinations of specimens of animal body tissues, fluids and secretions; diagnoses and dictates reports of findings. Reads and follows protocols in examining slides to determine initial requirements. Records all observations noting any abnormalities which might impact on the results of the study or lead to advanced or expanded explorations.

EDUCATION:

1969	Purdue University Ph.D. Pathology Thesis: "Ultrastructure of Isonicotinic Acid Hydrazide Induced Encephalopathy in the Peking Duck"
1966	Purdue University M.S. Pathology Thesis: "Uveitis, a Sequela to Experimentally Induced Leptospira Pomona Infection in the Shetland Pony"
1963	Iowa State University Dr. Veterinary Medicine

PROFESSIONAL EXPERIENCE:

1/83-11/95	Associate Director of Pathology Pharmaco LSR East Millstone, NJ 08875
5/79-1/83	Staff Pathologist Bio/dynamics, Inc. East Millstone, NJ 08875
1970-1979	Group Leader Lederle Laboratories Department of Experimental Pathology

Henry F. Bolte, D.V.M., Ph.D.

PROFESSIONAL EXPERIENCE - continued:

1968-1970	Administrative Assistant Purdue University Graduate Housing
1967-1970	Special Post-Doctoral Fellow
1964-1967	Graduate Instructor Purdue University Veterinary Pathology

PROFESSIONAL MEMBERSHIPS:

International Academy of Pathology
Society of Toxicologic Pathology
Mid-Atlantic Chapter of the Society of Toxicology
The New York Academy of Science
The American Association for the Advancement of Science
Phi Zeta
Phi Kappa Phi
Gamma Sigma Delta
Sigma Xi

PUBLICATIONS:

Bolte, H.F., Koralek, A.V., Traitor, C.E., "Toxicology Studies of Fenbufen", *Arzneim.-Forsch/Drug Res.* 30 (I). Nk 4a 91980. 721-728.

Rusch, G.M., Clary, John J., Rinehart, William E., and Bolte, Henry F., "A Twenty-Six Week Inhalation Toxicity Study with Formaldehyde in the Monkey, Rat and Hamster", *Toxicology and Applied Pharmacology*, 1982.

Rusch, George M., Bolte, Henry F., and Rinehart, William E., "A Twenty-Six Week Inhalation Toxicity Study with Formaldehyde in the Monkey, Rat and Hamster", *Formaldehyde Toxicity*, James E. Gibson, Ed., Hemisphere Publishing Company.

Andrews, L.S., Clary, John J., Terrill, J.B., and Bolte, Henry F., "Subchronic Inhalation Toxicity of Methanol", *Journal of Toxicology and Environmental Health* 20: 117-124 (1987).

Henry F. Bolte, D.V.M., Ph.D.

PUBLICATIONS - continued:

Atkinson, John E., Daly, Ira W., Bolte, Henry F., Morishima, Hideki and Sasaki, Satoshi. "One-Year Oral Gavage Toxicity Study of Lansoprazole (AG-1749) in Rats", *Japanese Pharmacology and Therapeutics* 18, Suppl. 10: 59 (S-2713)-91, (S-2745), 1990.

Wood, F.E., Tierney, W.J., Knezevich, A.L., Bolte, H.F., Maurer, J.K. and Bruce, R.D., Chronic Toxicity and Carcinogenicity Studies of Olestra in Fischer 344 Rats, *Food Chemical Toxicology*, Vol. 29, No. 4, pp. 223-230, 1991.

Newton, P.E., Bolt, H.F., Daly, I.W., Pillsbury, B.D., Terrill, J.B., Drew, R.T. and Sheldon, A.W., "Inhalation Toxicity of Antimony Trioxide", *Toxicology and Applied Pharmacology* (in press).

Nair, R.S., Johannsen, R.F., Bolte, H.F., Newton, P.E. and Rinehart, W.E., "Chronic Toxicity & Oncogenicity Study with CSM Fiber", *Toxicology and Applied Pharmacology* (in press).

Sumio Minematsu, John E. Atkinson, Henry F. Bolte, Hiroshi Sakai and Yuichi Fujii; A Subchronic (5-Month) Oral Toxicity Study of Tsumura Sho-saiko-to (TJ-9) in the Rat via Oral Gavage Administration with a 4-Week Recovery Period. *Oyo Yakuri/Pharmacometrics* 43 (1) 19-42 (1992).

Newton, P.E., Bolte, H.F., Daly, I.W., Pillsbury, B.D., Ben-Dyke, R., Drew, R.T. and Sheldon, A.W. "Subchronic and Chronic Inhalation Toxicity Studies of Antimony Trioxide in the Rat", *Fundamental and Applied Toxicology* 22, 561-576 (1994).

Atkinson, J.E., Bolte, H.F., Rubin, L.F. and Sonawane, Meena. "Assessment of Ocular Toxicity in Dogs During 6 Months Exposure to a Potent Organophosphate" *Journal of Applied Toxicology*, 14, 145-152 (1994).

ABSTRACTS:

R.D. McCabe, D.L. Reynolds, J. Schreurs, A. Childs, R.A. Braeckman, R.J. Zimmerman and H.F. Bolte, "Toxicology of M-CSF in Cynomolgus Monkeys by IV Infusion for 28-Days", *Toxicologist* 15, No. 1 (1995).

Nair, R.S., Johannsen, F.R., Bolte, H.F., Newton, P.E. and Rinehart, W.E. "Toxicity of Calcium Sodium Metaphosphate Fiber, II. Chronic Inhalation and Oncogenicity Study", *Fundamental and Applied Toxicology* 19: 79-90 (1992).

Henry F. Bolte, D.V.M., Ph.D.

ABSTRACTS - continued:

Nair, R.S., Johannsen, F.R., Bolte, H.F., Newton, P.E. and Rinehart, W.E. "Chronic Inhalation and Oncogenicity Study with Calcium Sodium Metaphosphate (CSM) Fiber", *Toxicologist* 11: 255 (1991).

Newton, P.E., Bolte, H.F. and Sheldon, A.W., "Pulmonary Toxicity after Chronic Inhalation Exposure to Antimony Trioxide (Sb_2O_3) in Rats, *Toxicologist* 10: 624 (1990).

Newton, P.E., Bolte, H.F. and Sheldon, A.W., "Pulmonary Toxicity after Chronic Inhalation Exposure to Antimony Trioxide (Sb_2O_3) in Rats, *J. Aerosol Medicine* 3: 78, 1990.

PRESENTATIONS:

Newton, P.E., Lake, L.K., Bolte, H.F. and Osimitz, T.G. "A Subchronic (4-Week) Inhalation Toxicity Study of a High Molecular Weight Emulsion Polymer in the Rat" (presented at the 31st Annual Society of Toxicology Meeting, Seattle, WA: February 1992).

"Evaluation of Reproductive Toxicity of Ortho-Dichlorobenzene (ODCB) in the Rat" (abstract): R. Nair, J. Barter, H. Bolte, R. Schroeder and C. Stack (presented at the V International Congress of Toxicology, July 1989).

I CERTIFY THAT THE ABOVE IS A TRUE AND ACCURATE ACCOUNT OF MY PROFESSIONAL HISTORY TO DATE.

SIGNED: _____

DATE: _____

CURRICULUM VITAE

NAME: Raymond E. Schroeder, M.S.

PRESENT POSITION: Project Manager
(since November 1995) Huntingdon Life Sciences Inc.
East Millstone, NJ 08875

Study Director responsibility for the performance of preclinical toxicity and safety assessment studies in small animal species particularly in the areas of developmental toxicity and reproduction/fertility.

EDUCATION:

1967 University of Illinois
Champaign/Urbana, Illinois
M.S. Zoology

1965 Wheaton College
Wheaton, Illinois
B.S. Biology

1974 Medical Pharmacology Course
Northwestern Medical School
Chicago, Illinois

PROFESSIONAL EXPERIENCE:

1990-1995 Sr. Toxicologist/Study Director
Pharmaco LSR Inc., Toxicology Services Worldwide
East Millstone, NJ 08875

1976-1990 Manager/Study Director
Reproduction/Teratology Department
Bio/dynamics, Inc.
East Millstone, NJ 08875

1975-1976 Manager
L.B. Allen, Inc.
Schiller Park, Illinois

1967-1975 Sr. Research Assistant (Teratology)
Searle Laboratories
Department of Pathology/Toxicology
Skokie, Illinois

Raymond E. Schroeder, M.S.

PROFESSIONAL ACCREDITATION:

Diplomate, American Board of Toxicology

PROFESSIONAL MEMBERSHIPS:

Mid-Atlantic Reproduction Teratology Association (MARTA) .
-Member Steering Committee 1977-1981
-Member Nominating Committee 1984-1985
Mid-Atlantic Society of Toxicology
Society of Toxicology
Society of Toxicology Reproductive Specialty Section
Teratology Society
Metropolitan New York Branch of AALAS (American
Association for Laboratory Animal Science)
Midwest Teratology Association (MTA)

PUBLICATIONS:

Carol S. Auletta, Raymond E. Schroeder, Walter J. Krasavage and Carol R. Stack, "Toxicology of Diethylene Glycol Butyl Ether, 4. Dermal Subchronic/Reproduction Study in Rats", *Journal of the American College of Toxicology*, Volume 12, Number 2, 1993.

Blacker, A.M., Schroeder, R.E., English, J.C., Murphy, S.J., Krasavage, W.J. and Simon, G.S. "A Two-Generation Reproduction Study with Hydroquinone in Rats", *Fundamental and Applied Toxicology* 21, 420-424 (1993).

Newton, P.E., Schroeder, R.E., Sullivan, J.B., Busey, W.M. and Banas, D.A. "Inhalation Toxicity of Phosphine in the Rat: Acute, Subchronic and Developmental", *Inhalation Toxicology* 5 (2): 233-239 (1993).

R.A. Kuna, M.J. Nicolich, R.E. Schroeder and G.M. Rusch, "A Female Rat Fertility Study with Inhaled Benzene", *Journal of the American College of Toxicology*, Volume 11, Number 3, 275-282 (1992).

S.J. Murphy, R.E. Schroeder, A.M. Blacker, W.J. Krasavage and J.C. English, "A Study of Developmental Toxicity of Hydroquinone in the Rabbit", *Fundamental and Applied Toxicology* 19, 214-221 (1992).

E.C. Robinson and R.E. Schroeder, "Reproductive and Developmental Toxicity Studies of a Linear Alkylbenzene Mixture in Rats", *Fundamental and Applied Toxicology* 18, Number 4, 549-556 (1992).

Raymond E. Schroeder, M.S.

PUBLICATIONS - continued:

S.C. Lewis, R.E. Schroeder and G.L. Kennedy, Jr., "Developmental Toxicity of Dimethylformamide in the Rat Following Inhalation Exposure", *Drug and Chemical Toxicology*, Vol. 15, Number 1, 1-14 (1992).

F.R. Johannsen, G.J. Levinskas, G.M. Rusch and R.E. Schroeder, "Subchronic Inhalation Toxicity and Reproductive Assessment in Rats of Three Chlorinated Propanes", *J. Toxicol. Environ. Health* Vol. Vol. 33 (No. 3), 291-302 (1991).

R.S. Nair, C.S. Auletta, R.E. Schroeder and F.R. Johannsen, "Chronic Toxicity, Oncogenic Potential, and Reproductive Toxicity of p-Nitroaniline in Rats", *Fundamental and Applied Toxicology*, Vol. 15, 607-621 (1990).

Biles, R.W., Schroeder, R.E. and C.E. Holdsworth; "Methyl Tertiary Butyl Ether Inhalation in Rats: A Single Generation Reproduction Study", *Toxicology and Industrial Health*, Vol. 3, No. 4, p. 519-534 (1987).

R.S. Nair, J.A. Barter, R.E. Schroeder, A. Knezevich and C.R. Stack, "A Two-Generation Reproduction Study with Monochlorobenzene Vapor in Rats", *Fundamental and Applied Toxicology*, Vol. 9, 678-686 (1987).

Conaway, C.C., Schroeder, R.E. and Snyder, N.K.; "Teratology Evaluation of Methyl Tertiary Butyl Ether in Rats and Mice", *Journal of Toxicology and Environmental Health*. Vol. 16, 797-809 (1985).

Nair, R.S., Johannsen, F.R. and Schroeder, R.E., "Evaluation of Teratogenic Potential of Paranitroaniline and Para-nitrochloro-benzene in Rats and Rabbits"; *Toxicity of Nitroaromatic Compounds*, Ed. by D.E. Rickert, Hemisphere Publishing Corporation, Washington, 1985; pp. 61-85.

Homan, E.R., Schroeder, R.E. "Inhalation Teratology Studies on Cyclohexanone", presented at "A Symposium on an Industry Approach to Chemical Risk Assessment-Caprolactam and Related Compounds as a Case Study"; (Abstract) published in the *Proceedings of a Symposium on An Industry Approach to Chemical Risk Assessment*, May, 1984, pp. 206-218.

Daly, I.W., Schroeder, R.E., and Killeen, J.C. "A Teratology Study of Topically Applied Linear Alkylbenzene Sulphonate in Rats"; *Food Cosmetic Toxicology*. Vol. 18, 55-58 (1980).

Ranney, R.E., Radzialowski, R.M., Mares, S.E., Schroeder, R.E. and Hutsell, T.C. "The Phenylalanine and Tyrosine Content of Maternal and Fetal Body Fluids from Rabbits Fed SC-18862"; *Toxicology and Applied Pharmacology*. Vol 32, 339-346 (1975).

Raymond E. Schroeder, M.S.

PRESENTATIONS:

Hoffman, G.M. and R.E. Schroeder; "A nose-only inhalation developmental toxicity study in rats comparing naive 'untrained' to tube acclimated 'trained' animals." Presented by poster at the Sixteenth annual meeting of the American College of Toxicology, November, 1995)

Carney, E.W., Schroeder, R. and W.J. Breslin; "Developmental Toxicity Study in Rats with Fluroxypyr methylheptyl ester"; *Teratology*, Vol. 51, No. 3, March 1995. (Presented by poster at the 35th Annual Meeting of the Teratology Society, June, 1995).

Carney, E.W., Schroeder, R. and W.J. Breslin; "Developmental Toxicity Study in Rats with Nitrapyrin"; *Teratology*, Vol. 51, No. 3, March 1995. (Presented by poster at the 35th Annual Meeting of the Teratology Society, June, 1995).

Schroeder, R.E., Newton, P.E., Rusch, G.M., and Trochimowicz, H.F.; "Inhalation Developmental Toxicity Studies with HCFC-123 and HCFC-124 in the Rabbit"; *Teratology*, Vol. 51, No. 3, March 1995. (Presented by poster at the 35th Annual Meeting of the Teratology Society, June, 1995).

Stephens, E., Nair, R., Carlton, B., Weiner, M., Smith, L. and Schroeder, R.; "Association of Liver Necrosis with Maternal Deaths in a One Generation Reproduction Study of Elemental Phosphorus". *The Toxicologist*, Vol. 12, No. 1, February 1992. (Presented by poster at the 31st Annual Meeting of the Society of Toxicology, February, 1992).

Bannister, R.M., Brewster, D.W., Rodwell, D.E., Schroeder, R.E. and Barnett, J.W., Jr. "Developmental Toxicity Studies in Rats with 4-Aminodiphenylamine (4-ADPA) and 4-Nitrodiphenylamine (4-NDPA)". *The Toxicologist*, Vol. 12, No. 1, February 1992. (Presented by poster at the 31st Annual Meeting of the Society of Toxicology, February, 1992).

"R.E. Schroeder, P.E. Newton, J.B. Sullivan and W.M. Busey. "An Inhalation Developmental Toxicity Study of Phosphine in Rats". *The Toxicologist*, Vol 12, No. 1, February 1992. (Presented by poster at the 31st Annual Meeting of the Society of Toxicology, February, 1992).

Blacker, A.M., Schroeder, R.E., English, J.C., Murphy, S.J. and Krasavage, W.J. "A Two-Generation Reproduction Study with Hydroquinone in Rats". *Teratology*, Vol. 43, No. 5, June, 1991. (Presented by poster at the 31st Annual Meeting of the Teratology Society, June, 1991).

Schroeder, R.E., Gerhart, J.M. and Kneiss, J. "Developmental Toxicity Studies of Tributyl Phosphate in the Rat and Rabbit". *Teratology*, Vol. 43, No. 5, June, 1991. (Presented by poster at the 31st Annual Meeting of the Teratology Society, June, 1991).

T.R. Hanley Jr., R.E. Schroeder and W.J. Breslin. "Developmental Studies on a Series of 2,4-D Salts and Esters in the Rat" *The Toxicologist*, Vol 11, No. 1, February 1991. (Presented by poster at the 30th Annual Meeting of the Society of Toxicology, February, 1991).

PRESENTATIONS - continued:

W.J. Breslin, R.E. Schroeder and T.R. Hanley Jr. "Developmental Toxicity of Picloram Potassium (L) and Triisopropanolamine (TIPA) Salts in the Rat" *The Toxicologist*, Vol 11, No. 1, February 1991. (Presented by poster at the 30th Annual Meeting of the Society of Toxicology, February, 1991).

C.S. Auletta, R.E. Schroeder, W.J. Krasavage and C. Stack "Toxicology of Diethylene Glycol Butyl Ether: 3. Dermal Subchronic Toxicity/Fertility Study in Rats". *The Toxicologist*, Vol. 11 No. 1, February 1991. (Presented by poster at the 30th Annual Meeting of the Society of Toxicology, February, 1991).

S.J. Murphy, R.E. Schroeder, A.M. Blacker, W.J. Krasavage and J.C. English "Study of Developmental Toxicity of Hydroquinone (HQ) in the Rabbit". *The Toxicologist*, Vol. 11, No. 1, February 1991. (Presented by poster at the 30th Annual Meeting of the Society of Toxicology, February, 1991).

R. Nair, J. Barter, H. Bolte, R. Schroeder and C. Stack. "Evaluation of Reproductive Toxicity of Ortho-Dichlorobenzene (ODCB) in the Rat" (abstract); (presented at the V International Congress of Toxicology, July 1989).

R.S. Nair, F.R. Johannsen, C.S. Auletta and R.E. Schroeder. "Chronic Toxicity and Potential Reproductive Effects of P-Nitroaniline (PNA) in the Rat". *The Toxicologist*, Vol. 7, No. 1, February 1987. (Presented by poster at the 26th Annual Meeting of the Society of Toxicology, February, 1987).

R.S. Nair, F.R. Johannsen and R.E. Schroeder. "Absence of Teratogenic Response in Rats and Rabbits Given a Detergent Builder". *The Toxicologist*, Vol. 7, No. 1, February 1987. (Presented by poster at the 26th Annual Meeting of the Society of Toxicology, February, 1987).

E.C. Robinson, R.D. Short, F.R. Johannsen and R.E. Schroeder. "A Teratology Study of a Mixture of Decyldodecyl Benzenes". *The Toxicologist*, Vol. 7, No. 1, February 1987. (Presented by poster at the 26th Annual Meeting of the Society of Toxicology, February, 1987).

R.E. Schroeder, I.W. Daly and V.J. Theodorides. "A Teratology Study in Rats with Virginiamycin". *The Toxicologist*, Vol. 7, No. 1, February 1987. (Presented by poster at the 26th Annual Meeting of the Society of Toxicology, February, 1987).

Biles, R.W., Schroeder, R.E. and Holdsworth, C.E., "Single Generation Reproduction Study of Methyl-T-Butyl Ether in Rats", *The Toxicologist* Vol. 6, No. 1, 1986. (Presented by poster at the 25th Annual Meeting of the Society of Toxicology, March, 1986).

Schroeder, R.E., Terrill, J.B., Lyon, J.P., Kaplan, A.M. and Kimmerle, G., "An Inhalation Teratology Study in the Rabbit with Nitrobenzene", *The Toxicologist*. Vol. 6, No. 1, 1986. (Presented by poster at the 25th Annual Meeting of the Society of Toxicology, March, 1986).

-6-

Raymond E. Schroeder, M.S.

PRESENTATIONS - continued:

Parker, J.A., MacGregor, J.A. and Schroeder, R.E., "Diet Restriction During Gestation in NZW Rabbits Does Not Adversely Affect Fetal Outcome", *Teratology*. Vol. 33, pp. 71 C 1986 (Presented by poster at the 26th Annual Meeting of the Teratology Society, July, 1986).

Nair, R.S., Johannsen, F.R., Levinskas, G.J., and Schroeder, R.E., "A Rat Teratology Study with Tetrathal", presented at the Federation of American Societies for Experimental Biology (FASEB), April 1984.

Lewis, S.C., Rinehart, W.E., Schroeder, R.E., Thackara, J.W. "Dominant Lethal Mutagenic Bioassay Dimethyl Formamide (DMF)"; *Environmental Mutagen Society* (abstract) (1979).

Schroeder, R.E., Vondruska, J.F. and Youkilis, L.J. "Teratological Evaluations of a Copper Containing Intrauterine Device (CuIUD) in Rats and Rabbits"; (abstract); *Teratology*. Vol. 3, (1975).

Bost, R.G., McConnell, R.G., Rao, K.S., Reno, F.E., Schroeder, R.E., and Vondruska, J.F. "An Evaluation of the Mutagenic Potential of Aspartame and SC-19192"; *American College of Nutrition* (abstract) (1974).

McConnell, R.G., Rao, K.S., Reno, R.F., Schroeder, R.E., Trutter, J. and Vondruska, J.F. "Fertility, Reproduction and Teratology Studies with Aspartame and SC-19192"; *American College of Nutrition* (abstract) (1974).

REPORTS ON PROPRIETARY COMPOUNDS SUBMITTED TO SPONSORS:

Numerous confidential preclinical toxicity reports in the areas of general toxicity, reproduction/fertility, developmental toxicity and mutagenicity (i.e., dominant-lethal studies). These reports are prepared for Pharmaceutical, Agricultural and Industrial Chemical, Food Additive and Cosmetic Industries for submission to regulatory agencies around the world.

I CERTIFY THAT THE ABOVE IS A TRUE AND ACCURATE ACCOUNT OF MY PROFESSIONAL HISTORY TO DATE.

SIGNED Raymond E. Schroeder DATE: 1 Dec 85

CURRICULUM VITAE

NAME: Ira W. Daly, Ph.D.
Diplomate, American Board of Toxicology

PRESENT POSITION: Vice President, Agrochemical & Industrial
(since November 1995) Toxicology
Huntingdon Life Sciences
East Millstone, NJ 08875

Acts as the client representative on site. Responsible for maintaining communication with client without impeding direct communication between client and study management. Acts as program director for multidisciplinary projects to ensure that precise requirements of the client are fully understood and met and to be available to provide client with appropriate advice and consultancy. Develops appropriate protocols and programs to provide the most scientifically valid and cost-effective solution to the client's requirements which will be acceptable to regulatory agencies. Responsible to senior management for the quality of service provided to clients.

EDUCATION:

1977 St. John's University
Jamaica, New York
Ph.D. Pharmacology

1974 St. John's University
Jamaica, New York
M.S. Pharmacology

PROFESSIONAL EXPERIENCE:

1993-1995 Vice President, Business Development Operations
1989-1993 Sr. Vice President & Director of Toxicology
Pharmaco LSR Inc., Toxicology Services Worldwide
East Millstone, NJ 08875
1985-1989 Vice President and Director of Toxicology
1982-1985 Director of Toxicology
1980-1982 Associate Director of Toxicology/Operations
1978-1980 Staff Toxicologist/Study Director
Bio/dynamics, Inc.
East Millstone, NJ 08875

1979-1980 Adjunct Assistant Professor
Graduate School of Allied Health Professions
St. John's University, Jamaica, New York

Ira W. Daly, Ph.D.

PROFESSIONAL EXPERIENCE - continued:

1977-1978

Supervisor, Applied Pharmacology/Consultant Toxicologist
Department of Biological Sciences and Clinical Affairs
American Chicle Division of Warner Lambert Company
Morris Plains, New Jersey

Conducted in-house toxicity studies, monitored contract toxicological investigations. Managed laboratory in the areas of basic and applied Gastrointestinal and Respiratory Pharmacology. Conducted clinical investigations in Gastrointestinal Pharmacology.

PROFESSIONAL ACCREDITATION:

Diplomate, American Board of Toxicology (1980)
Regulatory Affairs Certification (1992)

PROFESSIONAL APPOINTMENTS:

Technical Committee - Society of Toxicology (1984-1986)

PROFESSIONAL MEMBERSHIPS:

Society of Toxicology
European Society of Toxicology
Society of Toxicology Reproductive Specialty Section
Mid-Atlantic Chapter of the Society of Toxicology
Society of Environmental Toxicology and Chemistry

PUBLICATIONS AND PRESENTATIONS:

Carol S. Auletta, Lionel F. Rubin, Ira W. Daly, Ward R. Richter, Kazuhiro Hosoi, Hiroshi Suda and Toshimi Ikuse; "26-Week Ocular Toxicity Studies in Pigmented Rabbits Treated Topically with Bunazosin Hydrochloride Ophthalmic Solution"; *Atarashi Ganka (J.Eye)*, Vol. 12, No. 3, 1995.

Newton, P.E., Bolte, H.F., Daly, I.W., Pillsbury, B.D., Ben-Dyke, R., Drew, R.T. and Sheldon, A.W. "Subchronic and Chronic Inhalation Toxicity Studies of Antimony Trioxide in the Rat", *Fundamental and Applied Toxicology* 22, 561-576 (1994).

"Validation of a Neurotoxicity Screening Battery" (presented at the 33rd Annual Society of Toxicology Meeting, March 1994).

"Validation of a Developmental Neurotoxicity Screening Battery: Effects of Hydroxyurea, Methylmercuric Chloride and Diphenylhydantoin". K.E. Sloan, W.R. Richter, C.S. Auletta and I.W. Daly (presented at the 31st Annual Society of Toxicology Meeting, February 1992).

Ira W. Daly, Ph.D.

PUBLICATIONS AND PRESENTATIONS - continued:

"Oncogenicity Study of AO-128 in Mice", *Japanese Pharmacology and Therapeutics* 19, 131-142 (1991).

"One-Year Oral Gavage Toxicity Study of AO-128 in Rats", *Japanese Pharmacology and Therapeutics* 19, 233-260 (1991).

"One-Year Oral Toxicity Study of AO-128 in Beagle Dogs", *Japanese Pharmacology and Therapeutics* 19, 261-282 (1991).

"Subchronic Oral Toxicity of Cellulose Acetate in Rats", *Food and Chemical Toxicology* 29, 453-458 (1991).

"One-Year Oral Gavage Toxicity Study of Lansoprazole (AG-1749) in Rats", *Japanese Pharmacology and Therapeutics* 18, 59-91 (1990).

"One-Year Oral Gavage Toxicity Study of Lansoprazole (AG-1749) in Dogs", *Japanese Pharmacology and Therapeutics* 18, 93-118 (1990).

"Malignant Hyperthermia Induction in Susceptible Swine Following Exposure to Arduan" (presented at the International Anesthesia Research Society 64th Congress, March 1990, Honolulu, HI).

"A Subchronic Oral Toxicity Study with Cellulose Acetate" (presented at the 29th Annual Meeting of the Society of Toxicology, February 1990). *The Toxicologist* 10, #670 (1990).

"Subchronic Inhalation Toxicity of Ethylbenzene in Mice, Rats and Rabbits", *Fundamental and Applied Toxicology* 13, 399 (1989).

"Subchronic Inhalation and Oral Toxicity of Hydrogenated Terphenyls in Rats", *Fundamental and Applied Toxicology* 13, 559 (1989).

"Subchronic Inhalation Toxicity of Ethylbenzene in Mice, Rats and Rabbits" (presented at the 28th Annual Meeting of the Society of Toxicology, March 1989), *The Toxicologist*, 9 (1) 1989.

"Human Safety Studies with Albendazole" (presented at the Proceedings of the American Association of Veterinary Parasitologists, 34th Annual Meeting, July 1989) Orlando, FL.

"Cardiac Performance and Hemodynamics in Malignant Hyperthermia Susceptible and Normal Pigs During Sevoflurane Anesthesia" (presented at the 42nd Post Graduate Assembly in Anesthesiology, December 1988).

"A Teratology Study in Rats with Virginiamycin" (presented at the 26th Annual Meeting of the Society of Toxicology, February 1987), *The Toxicologist* 7 (1) 1987.

Ira W. Daly, Ph.D.

PUBLICATIONS AND PRESENTATIONS - continued:

"A Two-Generation Reproduction Study in Rats with Virginiamycin" (presented at the 26th Annual Meeting of the Society of Toxicology, February 1987); *The Toxicologist* 7 (1) 1987.

"Chronic Toxicity and Oncogenicity Studies of LASSO (Alachlor) Herbicide in Rodents" (presented Fourth International Congress of Toxicology, July 1986); *Toxicology Letters*, 31 (Suppl.) 56 (1986).

"Dose-Dependent Clearance of Antimony from Rat Lungs" (presented Society of Toxicology, March 1986); *The Toxicologist* 6-(1) 36 (1986).

"Ectopic Pupil in Mice", *Laboratory Animal Science*, 32 (1) 1982.

"Subchronic Toxicity of Chloropropanol in Rats and Dogs" (presented Society of Toxicology, San Diego, 1981).

"A Teratology Study of Topically Applied Linear Alkylbenzene Sulfonate in Rats", *Food and Cosmetic Toxicology*, Vol. 18, 1980.

"The Effect of Prostaglandins PGE2 and PGF2A on Spermatogenesis in Adult Male Sprague-Dawley Rats" (presented ASPET August 1977); *International Journal of Fertility*, 24 (3) 1979.


"Testicular Morphology Following Prostaglandin Administration" (presented ASPET, August 1977); *The Pharmacologist*, 19 (2) 523 (1977).

"Effects of d-Amphetamine Sulfate on Aggressive Behavior in Laboratory Mice", *Clinical Toxicology*, 8 (3) 1975.

REPORTS ON PROPRIETARY COMPOUNDS SUBMITTED TO SPONSORS:

Approximately 1500 confidential reports on acute, sub-chronic, chronic, reproduction/teratology and inhalation studies in rodent and higher animal species. These reports were issued to the pharmaceutical, agricultural, industrial chemical and food additive industries.

I CERTIFY THAT THE ABOVE IS A TRUE AND ACCURATE ACCOUNT OF MY PROFESSIONAL HISTORY TO DATE

SIGNED 

DATE 7 Dec 95

CURRICULUM VITAE

NAME: Teresa S. Kuszniir, V.M.D.

PRESENT POSITION: Veterinarian, Toxicology Department
(since November 1995) Huntingdon Life Sciences Inc.
East Millstone, NJ 08875

Responsibilities include the development, implementation and maintenance of animal care standards for animals utilized (non-human primates, dogs, rodents, rabbits, birds and others with an average monthly census of approximately 9,000). Responsibilities also include assurance of compliance with local and federal laboratory animal regulations as well as AAALAC standards.

EDUCATION:

1993 University of Pennsylvania
Philadelphia, PA
V.M.D.

1982 Delaware Valley College of Science and Agriculture
Doylestown, PA
B.S. Animal Husbandry

PROFESSIONAL LICENSING: Pennsylvania

PROFESSIONAL EXPERIENCE:

1995 Veterinarian, Toxicology Department
Pharmaco LSR Inc., Toxicology Services Worldwide
East Millstone, NJ 08875

1973-1995 Post Doctoral Fellow, Laboratory Animal Science
SmithKline Beecham Pharmaceuticals
Swedeland, PA

Responsibilities included the complete medical and surgical care of various species of research animals within R&D, including non-human primates, dogs, rodents, swine and rabbits. Provided veterinary consultation and surgical services to investigators including, but not limited to, implantation of vascular and gastrointestinal access devices. Additional responsibilities included necropsy and clinical diagnostics. Facilitated technical training programs, including SB 1995 Investigator Training Seminar "Post-Operative Care and Monitoring of Lab Animals", and "Techniques in Anesthesia", L.A.S.T.S. Seminar.

1991-1991 Associate Scientist, Department of Investigative Pathology

Conducted hepatocellular proliferation studies in rats. Technical duties included dosing rats, surgical implantation of BrDU osmotic pumps, necropsy and terminal collection of liver samples. Further responsibilities included reading liver slides, assessing hepatic labeling indices, correlating and graphing data and presenting results to senior staff.

Teresa S. Kuszniir, V.M.D.

PROFESSIONAL EXPERIENCE:

1990-1990

Associate Scientist, Department of Immunology

Conducted experiments on murine models of endotoxin shock and effects of various inhibitors of shock, cyclo-oxygenase and lipoxygenase pathways. Performed ELISA assays to measure TNF levels of these models. Duties included media and drug preparation, dosing and bleeding. Utilized computer graphics and word processing software for data summarization. Assisted in experiments on the inhibition of rheumatoid arthritis in rats.

1987-1989

Associate Toxicologist, Investigative Toxicology Unit

Conducted pre-clinical in-vivo toxicity studies in various species of laboratory animals and evaluated the resulting data. Duties included drug preparation, delivery of test article to animals by standard and novel routes, phlebotomy, assessing non-invasive blood pressures and EKGs in dogs and primates, performing necropsies and identifying gross pathology. Various computer skills utilized in report production word processing and generation of graphics by RSE.

1984-1986

Research Technician, Toxicology
Wyeth Laboratories
Great Valley, PA

Responsible for carrying out drug safety evaluation studies in rats, mice, dogs and primates. Duties also included dosing, performing necropsies, maintaining accurate records, preparing drug and obtaining physiological specimens. Prepared Standard Operating Procedures for compliance with GLP regulations. Special projects included long term maintenance of drug induced diabetic monkeys and radiolabeled drug metabolism studies in dogs.

1983-1984

Veterinary Technician/Adoption Coordinator
Morris Animal Refuge
Philadelphia, PA

Provided general veterinary care to all shelter animals, including physical exams, treatments, vaccination, grooming, euthanasia and kennel duties. Also interviewed pet adopters and educated same in responsible pet ownership.

1976-1982

Veterinary Technician/Receptionist
Hopewell Veterinary Hospital
Philadelphia, PA

Responsible for assisting veterinarians with appointments, treatments, x-rays, surgeries and post-op care of animals. Performed routine lab work including heartworm tests, fecals, urinalyses, hematocrits and ultrasonic teeth cleaning. Additional responsibilities included clerical work, hiring, training and scheduling of part-time employees.

Teresa S. Kuszniir, V.M.D.

I CERTIFY THAT THE ABOVE IS A TRUE AND ACCURATE ACCOUNT OF MY
PROFESSIONAL HISTORY TO DATE.

SIGNED

Teresa S. K.

DATE

4 Dec 95

CURRICULUM VITAE

NAME: Ward R. Richter, D.V.M., M.S.
Diplomate, American College of Veterinary Pathologists

PRESENT POSITION: Vice President & Scientific Director
(since 11/93) Huntingdon Life Sciences Inc.
East Millstone, NJ 08875

Responsible for all scientific and technical operations including toxicology, pathology, chemistry and computer operations. Interface with clients on scientific issues.

EDUCATION:

1962 Iowa State University, IA
M.S. Pathology

1955 Iowa State University, IA
D.V.M.

1951 University of Wisconsin, WI
Pre-Veterinary

VETERINARY LICENSE:

Iowa and Illinois, inactive status

PROFESSIONAL EXPERIENCE:

7/91-11/93 Vice President & Director of Pathology

Responsibilities included organizing and directing the Department of Pathology (a department comprised of approximately 45 professional and technical staff) and interfacing with clients on matters of Pathology.

1990-7/91 President
Kemdru International, Inc. (A Safety
Assessment Consulting Firm)
Evansville, IN

1989-1990 Coordinator, Pesticide Product Safety
Chevron Environmental Health Center
Richmond, CA

1983-1991 Vice President
Toad Hall Systems, Inc. (A Software Development Firm specializing in
Systems for Toxicology & Pathology Laboratories)
Union Grove, WI

Ward R. Richter, D.V.M., M.S.

PROFESSIONAL EXPERIENCE - continued:

1985-1989	Chief of Pathology, Genetic Toxicology & Reproductive Toxicology Chevron Environmental Health Center Richmond, CA
1980-1985	Director, Pathology Division International Research and Development Corp. Manawan, MI
1977-1985	Professor (Collaborator Basis) Department of Veterinary Pathology Iowa State University, IA
1973-1980	Director A.J. Carlson Animal Research Facility University of Chicago, IL
1973-1980	Professor, Department of Pathology University of Chicago, IL
1973-1980	Professor, The College University of Chicago, IL
1969-1972	Deputy Director A.J. Carlson Animal Research Facility University of Chicago, IL
1968-1973	Associate Professor of Comparative Pathology University of Chicago, IL
1964-1977	Associate Professor (Collaborator Basis) Department of Veterinary Pathology Iowa State University, IA
1967-1968	Clinical Associate Professor Department of Oral Biology Loyola University, Chicago, IL
1963-1968	Head, Cellular Pathology and Electron Microscopy (Pathology Department) Abbott Laboratories, North Chicago, IL

Ward R. Richter, D.V.M., M.S.

PROFESSIONAL EXPERIENCE - continued:

1961-1963	Research Associate (Pathology Department) University of Louisville School of Medicine Louisville, KY
1960-1963	Chief, Cellular Pathology Branch (Pathology Department), U.S. Army Medical Research Laboratory, Ft. Knox, KY
1958-1960	Instructor, Veterinary Pathology Iowa State University, IA

SOCIETY MEMBERSHIPS:

American College of Veterinary Pathologists
American College of Toxicology
Society of Toxicological Pathologists
United States & Canadian Academy of Pathology
American Society for Investigative Pathology
American Association for the Advancement of Science
American Veterinary Medical Association
International Society for the Study of Xenobiotics

HONORS AND HONOR SOCIETIES:

Alumni Merit Award (Iowa State University
Alumni Association, 1971)
Alpha Zeta
Phi Zeta
Phi Kappa Phi
Sigma Xi
Outstanding Service Award (Charles Louis Davis,
D.V.M. Foundation, 1981)

SPECIALTY BOARD:

Diplomate, American College of Veterinary
Pathologists (1966)

SPECIAL CONSULTANTSHIPS AND COMMITTEE MEMBERSHIPS:

1957-1958	Faculty Advisor to Pre-Vet Club, Iowa State University
-----------	--

Ward R. Richter, D.V.M., M.S.

SPECIAL CONSULTANTSHIPS AND COMMITTEE MEMBERSHIPS - continued:

1958-1959	Admissions Committee, College of Veterinary Medicine, Iowa State University
1958-1959	Member Faculty Senate, Iowa State University
1965-1966	President, Midwest Society of Electron Microscopists
1966-1973	Special Lecturer and Consultant in Comparative Pathology, Resident Investigator Program in Laboratory Animal Medicine, V.A. Hospital, Hines, Illinois
1968-1969	Deputy Coroner, Lake County, Illinois
1969-1970	Director, Midwest Society of Electron Microscopists
1972-1973	Member of the Scientific Advisory Panel to Assistant Secretary of HEW on the safety of NTA as a detergent builder
1973	Meeting Arrangements Chairman for 1974 Meeting of American College of Veterinary Pathologists
1972-1973	Consultant to UAREP on long-term low level toxicity program development for the National Center for Toxicologic Research, Pine Bluff, Arkansas
1973	Member, Committee on Education, Society of Pharmacological and Environmental Pathologists
1973-1974	Consultant, Dental Research Institute Great Lakes Naval Training Station
1974-1975	Consultant, National Institute of Environmental Health Sciences
1974-1975	Consultant, Graduate Review Committee, Department of Pathology, University of Chicago

Ward R. Richter, D.V.M., M.S.

SPECIAL CONSULTANTSHIPS AND COMMITTEE MEMBERSHIPS - continued:

1974-1975	Consultant to HHHB Hospital Management Consultants, Chicago and San Francisco
1971-1978	Consultant, Argonne National Laboratories Argonne, Illinois
1974-1976	Member, Senior Scientific Advisory Board, National Center for Toxicologic Research, Jefferson, Arkansas
1976	Consultant, Medical Examiner Cook County, Illinois
1973-1979	Chairman, Committee on Animal Resources University of Chicago, Illinois
1969-1980	Representative to Council of National Society for Medical Research
1971-1980	Consulting Pathologist, Lincoln Park Zoo Chicago, Illinois
1973-1980	Midwest Program Director, Charles Louis Davis, D.V.M. Foundation
1974-1980	Consulting Pathologist, Berwyn Veterinary Medical Center, Berwyn, Illinois
1974-1980	Consultant, Carcinogenesis and Toxicology Illinois Institute of Technology Research Institute
1977-1981	Member, Editorial Board, Journal of Environmental Pathology and Toxicology
1979-1980	Vice President, Illinois Society for Medical Research Chicago, Illinois
1979-1980	Consultant to UAREP (FDA) for review and evaluation of Nitrite Carcinogenicity Studies
1979-1980	Consultant to Tracor-Jitco (NCI) for review of carcinogenic potential of Dioxanes
1973-1991	Faculty of Discussants, Charles Louis Davis, D.V.M. Foundation
1983	Advisory Board, Charles Louis Davis, D.V.M. Foundation

Ward R. Richter, D.V.M., M.S.

PUBLICATIONS:

Richter, W.R.: Tubular Adenomata of the Adrenal of the Goat, *Cornell Vet.* 47: 558-577, 1957.

Richter, W.R.: Adrenal Cortical Adenomata in the Goat, *American Jour. Vet. Res.* 19: 895-901, 1958.

Richter, W.R.: Observations on the Penile Development of the Angora Goat, *Am. Jour. Vet. Res.* 20: 603-606, 1959.

Pearson, P.T., Jensen, E.C. and Richter, W.R.: Urinary Calculi in a 2-Month Old Pup, *Jour. A.V.M.A.* 135: 329-331, 1959.

Thompson, J.H. and Richter, W.R.: Hematoxylin-Eosin Staining Adapted to Automatic Tissue Processing, *Stain Technology* 35: 145-148, 1960.

Richter, W.R.: The Electron Microscope and its Application to Medical Research, *Jour. A.V.M.A.* 140: 1304-1309, 1962.

Richter, W.R.: Electron Microscopic Observations on Transitional Epithelium of Dogs Infected with Canine Distemper. U.S. Army Res. Lab. Report #556, Fort Knox, Kentucky, 1962.

Richter, W.R.: Effects of RF Energy on Tissue Cultures, U.S. Army Med. Res. Lab. Report #600, Fort Knox, Kentucky, 1962.

Richter, W.R. and Moize, S.M.: Electron Microscopic Observations on the Collapsed and Distended Mammalian Urinary Bladder, *J. Ultrastructure Res.* 9: 1963.

Richter, W.R. and Yost, D.H.: A Morphological Study of Rat Testicular Tissue Exposed to RF Energy, U.S. Army Med. Res. Lab. Report #601, Fort Knox, Kentucky, 1964.

Richter, W.R., Shipkowitz, N.L. and Rdzok, E.J.: Oral Papillomatosis of the Rabbit, An Electron Microscopic Study, *Lab. Invest.* 13: 430-438, 1964.

Richter, W.R., Rdzok, E.J. and Moize, S.M.: Electron Microscopy of Virus-like Particles Associated with Duck Viral Hepatitis. *Virology* 24: 1964.

Cohen, A.I., Nicol, E.C. and Richter, W.R.: Nerve Growth Factor Requirement for Development of Dissociated Embryonic Sensory and Sympathetic Ganglia in Culture, *Proc. Soc. Exp. Bio. Med.* 116: 784-789, 1964.

Margoliash, E., Schenck, J.R., Hargie, M.P., Burokas, S., Richter, W.R., Barlow, G.H. and Mascona, A.A.: Characterization of Specific Cell Aggregating Materials from Sponge Cells. *Biochem. and Biophys. Res. Communications* 20: 383-388, 1965.

Richter, W.R., Stein, R.J., Rdzok, E.J., Moize, S.M. and Bischoff, M.B.: Ultrastructural Studies in Intranuclear Crystalline Inclusions in the Liver of the Dog. *Amer. J. Path.* 47: 587-599, 1965.

Ward R. Richter, D.V.M., M.S.

PUBLICATIONS - continued:

Smith, R.J., Richards, R.K., Richter, W.R., Hylton, R.R., McCabe, J.R. and Cullin, S.C.: Electrical Anesthesia Produced by Combining Direct and Alternating Currents: Electronmicroscopy of the Dog Brain. *Anesthesiology* 26: 607-611, 1965.

Rdzok, E.J., Shipkowitz, N.L. and Richter, W.R.: Rabbit Oral Papillomatosis, Ultrastructure of Experimental Infection. *Cancer Res.* 26: 160-165, 1966.

Richter, W.R., Bischoff, M.B. and Churchill, R.A. An Observation of Fine Tubules Within the Endoplasmic Reticulum in a Dog Liver. *Zeitschrift fur Zellforschung* 70: 180-184, 1966.

Stein, R.J., Richter, W.R., Zussman, R.A. and Brynjolfsson, G.: Ultrastructural Characterization of Daphnia Heart Muscle. *Jour. Cell Biol.* 29: 168-170, 1966.

Stein, R.J., Richter, W.R. and Brynjolfsson, G.: Ultrastructural Pharmacopathology: I. Comparative Morphology of the Livers of the Normal Street Dog and Purebred Beagle. A Baseline Study. *Exp. and Mol. Path.* 5: 195-224, 1966.

Richter, W.R., Stein, R.J. and Blockus, L.E.: Experimental Production of Intramitochondrial Filaments in Dog Liver. *Proceed. 6th Int. Cong. for Electron Microscopy*: 615-616, Kyoto, 1966.

Bischoff, M.B. and Richter, W.R.: Some Ultrastructural Features of the Pineal Organ in Japanese Quail. *Proceed. 6th Int. Cong. for Electron Microscopy*: 523-524, Kyoto, 1966.

Gerard, J., Richter, W.R., Fenters, J. and Holper, J.C.: Biophysical Studies with Rhinoviruses Using Zonal Ultracentrifuge Systems. *Jour. Virology* 2: 937-943, 1968.

Stein, R.J., Richter, W.R., Rdzok, E.J., Moize, S.M. and Brynjolfsson, G.: Comparative Hepatic Ultrastructure of Subhuman Primates: A Baseline Study of Rhesus, African Green and Squirrel Monkeys in: *Use of Subhuman Primates in Drug Evaluation*, ed. by Harold Vagberg, University of Texas Press, Austin, 1968.

Bischoff, M.B., Richter, W.R. and Stein, R.J.: Ultrastructural Changes in Pig Hepatocytes During the Transitional Period from Late Foetal to Early Neonatal Life. *J. Cell Sci.* 4: 381-395, 1969.

Richter, W.R. and Moize, S.M.: Ultrastructural Nature of Canine Distemper Inclusions in the Urinary Bladder. *Path. Vet.* 7: 346-352, 1970.

Vesselinovitch, S.D., Mihailovich, N. and Richter, W.R.: The Induction of Malignant Melanomas in the Syrian White Hamster by Neonatal Exposure to Urethan. *Cancer Res.* 30: 2543-2547, 1970.

Ward R. Richter, D.V.M., M.S.

PUBLICATIONS - continued:

Port, C.D., Richter, W.R. and Moize, S.M.: An Ultrastructural Study of Tyzzer's Disease in the Mongolian Gerbil [*Meriones unguiculatus*]. *Lab. Invest.* 25: 81-87, 1971.

Richter, W.R., Zouhar, R.L., Tatsumo, J., Smith, R.H. and Cullen, S.C.: Electron Microscopy of the Macaca Mulatta Brain after Repeated Applications of Electrical Current. *Anesthesiology* 36: 374-377, 1972.

Churg, A. and Richter, W.R.: Histochemical Distribution of Carbonic Anhydrase after Ligation of the Pancreatic Duct. *Am. J. Path.* 68: 23-28, 1972.

Pine, J.H., Richter, W.R. and Esterly, J.R.: Experimental Bacterial Pneumonia. Ultrastructural, Autoradiographic and Histochemical Observations. *Amer. Jour. Path.* 73: 115-122, 1973.

Richter, W.R.: A Support Laboratory for Medical School Animal Research Facility. *Proceedings of National Conference on Research Animals in Medicine.* Washington, D.C., 1974.

Levin, S. and Richter, W.R.: A Systematic Method for the Detection of Experimentally Induced Hyperplasia and Early Neoplasia in the Urinary Bladder. *Toxicology and Applied Pharmacology* 27: 680-684, 1974.

Port, C.D., Baxter, D.W. and Richter, W.R.: The Mongolian Gerbil as a Model for Lead Toxicity I. Studies of Acute Poisoning. *Amer. Jour. Path.* 76: 79-94, 1974.

Torkelson, T.R., Leong, B.K.J., Kociba, R.R.J., Richter, W.R. and Gehring, P.J.: Lack of Manifestation of Toxicity in Rats Inhaling 111 ppm 1,4 Dioxane for Two Years. *Toxicology and Applied Pharmacology* 30: 1974.

Levin, S. and Richter, W.R.: Ultrastructure of Cell Surface Coat (Glycocalyx) in Rat Urinary Bladder Epithelium. *Cell Tissue Research* 158: 281-283, 1974.

Baxter, D.W., Port, C.D. and Richter, W.R.: Mongolian Gerbil as a Model for Chronic Lead Toxicity. *Jour. of Comparative Path.* 85: 1975.

Shybut, G.T., Richter, W.R. and Schuster, C.R.: Absence of Pathological Changes Following Intravenous Methamphetamine and IntraArterial Iothalamate Meglumine. *Research Communications in Chem. Path. and Path.* 15: 53-73, 1976.

Port, C.D. and Richter, W.R.: Eosinophilic Leukemia in a Syrian Hamster. *Vet. Path.* 14: 283-286, 1977.

Takara, A.N., Zaneveld, L. and Richter, W.R.: Laser-Induced Thermal Damage of Skin. *USAF school of Aerospace Medicine*, 1977.

Ward R. Richter, D.V.M., M.S.

PUBLICATIONS - continued:

Churg, A. and Richter, W.R.: Early Changes in the Exocrine Pancreas of the Dog and the Rat after Ligation of the Pancreatic Duct. A Light and Electron Microscopic Study. *Am. J. Path.* 63: 521-534, 1971.

Goyer, R.O., Falk, H., Feldman, Hogan, M. and Richter, W.R.: Renal Tumors in Rats Given Trisodium Nitrotriacetic Acid in Drinking Water for Two Years. *JNCI* 66: 86-89, 1981.

Shefner, A.M., Dooley, L., Ficks, A., Grubbs, C.J., Rust, J.R. and Richter, W.R.: Carcinogenicity of Diesel Exhaust Particles by Intratracheal Instillation-Dose Range Study. *Proceedings of International Symposium on the Health Effects of Diesel Engine Emissions*, 1981.

Holmes, P.A., Rust, J.H., Shefner, A.M. and Richter, W.R.: Long-Term Effects of TCDD and HCDD in Mice and Rats. *Health Effects of Halogenated Aromatic Hydrocarbons*, New York Academy of Sciences, 1981.

Levine, B.S., Henry, M.C., Port, C.D., Richter, W.R. and Urbanek, M.A.: Nephrotoxic Potential of cis-Diaminechloroplatinum and Four Analogs in Male Fischer 344 Rats. *JNCI*, 67: 201-206, 1981.

Schoenig, G.P., Goldenthal, E.I., Geil, R.G., Frith, C.H., Richter, W.R. and Carlborg, F.W.: Evaluation of the Dose Response and in utero Exposure to Saccharin in the Rat. *Food and Chem. Toxicol.* 23: 475-490, 1985.

Kuncl, R.W. and Richter, W.R.: Prevalence and Ultrastructure of Sarcocystis in Rhesus Monkeys. *Jpn J Vet Sci.* 50: 519-527, 1988.

Cushman, J.R., Richter, W.R. and Duke, J.T.: Effects of Skin Sensitization Test Wrapping on Guinea Pigs. *Contact Dermatitis* 21: 279-280, 1989.

Magaw, R.I., Richter, W.R. and MacGregor, J.A.: A Reexamination of Liver Tumors in Mice Exposed to Wholly Vaporized Unleaded Gasoline. *Jour. American College of Toxicology* 12: 195-199, 1993.

MacGregor, J.A., Richter, W.R. and Magaw, R.I.: Uterine Changes in Female Mice Following Lifetime Inhalation of Wholly Vaporized Unleaded Gasoline: A Possible Relationship to Observed Liver Tumors? *Jour. American College of Toxicology* 12: 119-126, 1993.

Daughtrey, W.D., Duffy, J.S., Haddock, L.S., Kernan, T.H. and Richter, W.R.: Chronic Inhalation Study of Commercial Hexane in Mice. *The Toxicologist* 14: 1234, 1994.

Ward R. Richter, D.V.M., M.S.

PUBLICATIONS - continued:

Carol S. Auletta, Lionel F. Rubin, Ira W. Daly, Ward R. Richter, Kazuhiro Hosoi, Hiroshi Suda and Toshimi Ikuse; "26-Week Ocular Toxicity Studies in Pigmented Rabbits Treated Topically with Bunazosin Hydrochloride Ophthalmic Solution"; *Atarashi Ganka (J.Eye)*, Vol. 12, No. 3, 1995.

Richter, W.R.: Author or Co-author of several hundred reports on preclinical safety studies (IRDC, 1980-1985 and at CEHC, 1985-1987).

I CERTIFY THAT THE ABOVE IS A TRUE AND ACCURATE ACCOUNT OF MY
PROFESSIONAL HISTORY TO DATE.

SIGNED: Ward R. Richter DATE: 9 Nov 95

CURRICULUM VITAE

NAME: T. Bill Waggoner, Ph.D.

PRESENT POSITION: Senior Scientist, Chemistry
(since 11/93) Huntingdon Life Sciences
East Millstone, NJ 08875

Overall responsibility for the technical aspects of Department of Chemistry, overseeing the activities of over 9 professional and technical staff. Responsible for all of the Residue, Environmental, Analytical Chemistry and Metabolism/Pharmacokinetics work conducted by the organization.

Responsible for the preparation of protocols and chemistry cost estimates, and for the preparation of final reports for completed studies to support regulatory submissions.

Reviews analytical procedures submitted by Sponsors and the development of appropriate methods of analysis. Coordinates in-house studies between other departments and outside contracting with clients and other laboratories.

EDUCATION:

1964	Michigan State University East Lansing, MI Ph.D. Organic Chemistry
1959	Oklahoma State University Stillwater, OK M.S. Biochemistry
1957	Oklahoma State University Stillwater, OK B.S. Chemistry

PROFESSIONAL EXPERIENCE:

7.92-11/93	Director of Metabolism & Analytical Chemistry Pharmaco LSR Inc.
------------	--

Overall responsibility for the Department of Metabolism and Analytical Chemistry, overseeing the activities of over 30 professional and technical staff. Responsible for all of the Residue, Environmental, Analytical Chemistry and Metabolism/Pharmacokinetics work conducted by the organization.

CMA 118518

T. Bill Waggoner, Ph.D.

PROFESSIONAL EXPERIENCE - continued:

1981-1984 Pesticides Registration Manager
Rhone Poulenc Ag Company (formerly Rhone Poulenc Inc.)
Monmouth Junction, NJ

Primary contact with the EPA for registration of pesticides and establishing crop tolerances.

1979-1981 Vice President
Analytical Development Corporation
Colorado Springs, CO

Head of technical staff of 30 providing support to Sponsor agrochemical and pharmaceutical companies - environmental fate and analytical chemistry.

1966-1978 Manager Biochemical Research
Mocay Corporation, Agricultural Chemicals Division
Kansas City, MO

Head, staff of 35 professional and technical staff for development of new pesticide active ingredients: radiosynthesis, metabolism, residue chemistry - moderate contact with EPA.

1964-1966 Senior Research Chemist
M&T Chemicals Incorporated, Electroplating Division
Detroit, MI

ACADEMIC EXPERIENCE:

1980 Visiting Assistant Professor
Colorado College
Colorado Springs, CO
•Organic chemistry and inorganic course and laboratory course

1960 Visiting Assistant Professor
Oklahoma State University
Stillwater, OK
•Advanced biochemical techniques; a course for graduate students and veterinary medicine students

PROFESSIONAL MEMBERSHIPS:

American Chemical Society

CMA 118519

T. Bill Waggoner, Ph.D.

PUBLICATIONS:

"Spectrofluorometric Determination of Bay Vp 2674 Residues in Poultry Tissue", J.A.O.A.C., 70, 815-818 (1987) with M.C. Bowman.

"Problems and Pitfalls in Biochemical Studies for Pesticide Toxicology", The Pesticide Chemist and Modern Toxicology, S.K. Bandel et al, editors, ACS Symposium Series 160, ACS, Washington, D.C. (1981).

"New Aspects of Organophosphorous Pesticides; VII. Metabolism, Biochemical and Biological Aspects of Nematicides and Related Phosphoramidate Compounds", Residue Reviews, Vol. 53 (1974)

PRESENTATIONS:

"Radiolabeled Compound Dosing Studies in Laboratory and Food Use Species for Tissue Residue Evaluations". Presented to The Association of Official Analytical Chemists Spring Workshop, Ottawa, Canada; Drug Residue Sessions Special Workshop (1981).

PATENTS:

Two patents from research at M&T Chemicals, Inc., Electroplating Division, Royal Oak, MI: topics were "plating on plastic materials" with E.J. Seyb (1967).

I CERTIFY THAT THE ABOVE IS A TRUE AND ACCURATE ACCOUNT OF MY PROFESSIONAL HISTORY TO DATE.

SIGNED: T. Bill Waggoner

DATE: 11/19/85

CMA 118520

Summary of Relevant Publications

Paul E. Newton, Ph.D., DABT

J.B. Knaak, T.R. Barfknecht, L.W. Smith and P.E. Newton, "Subchronic Inhalation Toxicity Study of p-Chlorobenzoatrimethylfluoride (PCBTF) in the Rat via Whole-Body Exposures", *The Toxicologist* 14, No. 1213, 1994.

P.E. Newton, W.L. Wooding and W.E. Rinehart, "An Inhalation Oncogenicity Study in Mice of Methyl ethyl ketoxime", *The Toxicologist* 14: No. 1220, 1994.

J.S. Duffy, L.S. Haddock, W.D. Daughtrey, T.H. Keenan and P.E. Newton, "Chronic Inhalation Study of Commercial Hexane in Rats", *The Toxicologist* 14: No. 1233, 1994.

Newton, P.E., Schroeder, R.E., Sullivan, J.B., Bussey, W.M., and Banas, D.A. "Inhalation Toxicity of Phosphine in the Rat: Acute, Subchronic and Developmental", *Inhalation Toxicology*, 5 (2): 233-239 (1993).

Ward R. Richter, D.V.M., M.S., ACVP

Daughtrey, W.D., Duffy, J.S., Haddock, L.S., Keenan, T.H. and Richter, W.R.: Chronic Inhalation Study of Commercial Hexane in Mice. *The Toxicologist* 14, 1234, 1994.

Magaw, R.I., Richter, W.R. and MacGregor, J.A.: A Reexamination of Liver Tumors in Mice Exposed to Wholly Vaporized Unleaded Gasoline. *Jour. American College of Toxicology* 12: 195-199, 1993.

MacGregor, J.A., Richter, W.R. and Magaw, R.I.: Uterine Changes in Female Mice Following Lifetime Inhalation of Wholly Vaporized Unleaded Gasoline: A Possible Relationship to Observed Liver Tumors? *Jour. American College of Toxicology* 12: 119-126, 1993.

Raymond E. Schroeder, M.S., DABT

Biles, R.W., Schroeder, R.E. and C.E. Holdsworth: "Methyl Tertiary Butyl Ether Inhalation in Rats: A Single Generation Reproduction Study", *Toxicology and Industrial Health*, Vol. 3, No. 4, p. 519-534 (1987).

R.S. Nair, J.A. Barter, R.E. Schroeder, A. Knezevich and C.R. Stack, "A Two-Generation Reproduction Study with Monochlorobenzene Vapor in Rats", *Fundamental and Applied Toxicology* 9, 678-686 (1987).

F.R. Johannsen, G.J. Levinskas, G.M. Rusch and R.E. Schroeder, "Subchronic Inhalation Toxicity and Reproductive Assessment in Rats of Three Chlorinated Propanes", *J. Toxicol. Environ. Health* 33 (3), 291-302 (1991).

Raymond E. Schroeder - continued:

R.A. Kuna, M.J. Nicolich, R.E. Schroeder and G.M. Rusch, "A Female Rat Fertility Study with Inhaled Benzene", *Journal of the American College of Toxicology*, Volume 11, Number 3, 275-282 (1992).

Conaway, C.C., Schroeder, R.E. and Snyder, N.K.; "Teratology Evaluation of Methyl Tertiary Butyl Ether in Rats and Mice", *Journal of Toxicology and Environmental Health* 16: 797-809 (1985).

Homan, E.R., Schroeder, R.E. "Inhalation Teratology Studies on Cyclohexanone", presented at "A Symposium on an Industry Approach to Chemical Risk Assessment-Caprolactam and Related Compounds as a Case Study"; (Abstract) published in the *Proceedings of a Symposium on An Industry Approach to Chemical Risk Assessment*, May, 1984, pp. 206-218.

Appendix B

HUNTINGDON LIFE SCIENCES

VINYL CHLORIDE COMBINED INHALATION TWO-GENERATION
REPRODUCTION AND DEVELOPMENTAL TOXICITY STUDY IN CD RATS

STUDY NO.: *

ISSUE NO.: 1

SPONSOR
STUDY NO: *

SPONSOR: CHEMICAL MANUFACTURERS ASSOCIATION

SPONSOR
REPRESENTATIVE: Hasmukh C. Shah, Ph.D

DATE: 5 December 1995

1 INTRODUCTION:

- 1.1 STUDY NO.: *
- 1.2 ISSUE NO.: 1
- 1.3 STUDY TITLE: Vinyl Chloride Combined Inhalation
Two-Generation Reproduction and
Developmental Toxicity Study in
CD Rats.
- 1.4 TEST MATERIAL: Vinyl Chloride
- 1.5 SPONSOR: Chemical Manufacturers
Association
2501 M Street, NW
Washington, DC 20037
- 1.6 SPONSOR REPRESENTATIVE: Hasmukh C. Shah, Ph.D.
Work - 202-887-1192
Fax - 202-887-4756
- 1.7 TESTING FACILITY: Huntingdon Life Sciences
Mettlers Road
P.O. Box 2360
East Millstone, NJ 08875-2360
- 1.8 PURPOSE:

The objectives of the combined inhalation two-generation reproduction and development toxicity study outlined in this protocol are to evaluate the effects of the test material on parental toxicity, reproductive capability, in utero development, and neonatal growth and survival in rats.

2 REGULATORY REFERENCES:

2.1 TEST GUIDELINE:

This study is designed to meet or exceed the guideline requirements of the EPA (Environmental Protection Agency: TSCA Test Guidelines (EPA, 1985); the Organization for Economic Co-operation and Development (OECD, Guidelines for testing of chemicals, Section 4: Health Effects, (OECD, 1981); and the European Economic Community (EEC), Methods for the Determination of Toxicity (EEC, 1988).

2.2 GOOD LABORATORY PRACTICES:

This study will be conducted in compliance with the FDA (Food and Drug Administration) Good Laboratory Practice (GLP) Regulations for nonclinical studies (FDA, 1988), the EPA TSCA Good Laboratory Practice Standards (EPA, 1990), the OECD Good Laboratory Practice Procedures (OECD, 1982) and the standard operating procedures of the Testing Facility.

2.3 FACILITIES MANAGEMENT/ANIMAL HUSBANDRY:

Currently acceptable practices of good animal husbandry will be followed, e.g., Guide for the Care and Use of Laboratory Animals; DHHS Publication No. (NIH) 86-23, Revised 1985. Huntingdon Life Sciences (East Millstone, NJ) is fully accredited by the American Association for Accreditation of Laboratory Animal Care (AAALAC).

2.4 ANIMAL WELFARE ACT COMPLIANCE:

This study will comply with all appropriate parts of the Animal Welfare Act regulations: 9 CFR Parts 1 and 2 Final Rules, Federal Register, Volume 54, No. 168, August 31, 1989, pp. 36112-36163 effective October 30, 1989 and 9 CFR Part 3 Animal Welfare Standards; Final Rule, Federal Register, Volume 56, No. 32, February 15, 1991, pp. 6426-6505 effective March 18, 1991. The Sponsor should make particular note of the following:

1. The Sponsor's signature on this protocol documents for the study described, there are no generally accepted non-animal alternatives and the study does not unnecessarily duplicate previous experiments.
2. All procedures used in this study have been designed to avoid discomfort, distress and pain to the animals. All methods are described in this study protocol or in written laboratory standard operating procedures.
3. Any aspects of this study which cause more than momentary or slight pain or distress to the animals will be performed with appropriate sedatives, analgesics or anesthetics unless the withholding of these agents is justified for scientific reasons, in writing by the Sponsor and the Study Director, in which case the procedure will continue for the minimum time necessary.
4. Animals that experience severe or chronic pain or distress that cannot be relieved will be painlessly euthanatized as deemed appropriate by the Testing Facility's veterinary staff and the Study Director. The Sponsor will be advised by the Study Director of all circumstances which could lead to this action in as timely a manner as possible.

2.4 ANIMAL WELFARE ACT COMPLIANCE:

5. Methods of euthanasia used during this study are in conformance with the above referenced regulations.

3 QUALITY ASSURANCE MONITORING:

The Huntingdon Life Sciences Quality Assurance Unit (East Millstone, NJ) will monitor the facilities, equipment, personnel, methods, practices, records and controls used in this study to assure that they are in conformance with this protocol, company standard operating procedures, and the appropriate Good Laboratory Practice regulations.

4 ALTERATION OF DESIGN:

Alterations of this protocol may be made as the study progresses. No changes in the protocol will be made without the consent of the Sponsor. In the event that the Sponsor authorizes a protocol change verbally, such changes will be honored by the Testing Facility and will be followed by a written verification. All protocol modifications will be signed by the Study Director and a Sponsor representative. Any modifications potentially affecting animal welfare will also be signed by two members of the Institutional Animal Care and Use Committee prior to the modification's implementation.

5 STUDY PERSONNEL:

Study Director:	*
Director of Inhalation Toxicology:	*
Study Pathologist:	*

Additional personnel will be documented in the project file and presented in the final report.

6 PROPOSED STUDY DATES:

Reproduction Study:

Initiation date:	Date Study Director Signs protocol - See Section 18.2.
Receipt of test animals:	*(to be addressed by amendment)
Initiation of exposures (P_1): (Experimental start date)	*
Termination of exposures (P_1):	*
Selection (P_2 from the F_1):	*
Termination of exposures (P_2):	*
Necropsy	
P_1 :	*
P_2 :	*

Developmental Toxicity Study:

Receipt of test animals:	*
Initiation of mating:	*
Initiation of exposures (first Day 6 gestation):	*
Termination of exposures (last Day 19 gestation):	*
Experimental termination: (date of last data collection)	*
Submission of draft final report:	*
Study completion date:	Date final report is signed by Study Director.

7 EXPERIMENTAL DESIGN:

7.1 Two-generation Reproduction Study:

Group	Exposure Level (ppm)	Number of Animals							
		Mated Adults				Microscopic Pathology Adult Generations ^b			
		P ₁		P ₂		P ₁		P ₂	
		M	F	M	F	M	F	M	F
I (control)	0 ^a	30	30	30	30	30	30	30	30
II	10	30	30	30	30	A.R.	A.R.	A.R.	A.R.
III	100	30	30	30	30	A.R.	A.R.	A.R.	A.R.
IV	1100	30	30	30	30	30	30	30	30

^a Control animals will be chamber-housed and sham-treated with clean room air for a comparable period of time as the test animals.

^b Histologic examinations will be performed for tissues listed in Appendix A.

Key: A.R. = As Required; 1) tissues that demonstrate treatment-related histologic changes in Group IV (additional cost); 2) gross lesions from animals found dead or euthanatized in a moribund condition during the study (additional cost); and 3) gross lesions terminal animals (additional cost); M = Male; F = Female.

7.2 Developmental Toxicity Study:

The developmental toxicity study will be performed with a unique population of animals during the exposure period for the P₁ parental animals. This will be during the mating and gestation periods for the F₁ pregnancies when animals are being exposed 7 days/week. Animals in the developmental toxicity study will be exposed in the chamber along with the animals in the two-generation reproduction study.

Group	Exposure Levels (ppm)	Treatment Schedule	Number of Animals				
			Mated	Sacrificed ^a	Proportion of Gestation Day 20 Fetuses/Litter Malformation/Variation Evaluations		
				Gestation Day 20	External	Soft Tissue	Skeletal
I (chamber - housed, sham air control)	0	Gestation Days 6-19	25	A.S.	All	½	½
II	10	Gestation Days 6-19	25	A.S.	All	½	½
III	100	Gestation Days 6-19	25	A.S.	All	½	½
IV	1100	Gestation Days 6-19	25	A.S.	All	½	½

^a Gross postmortem examination, liver and kidneys will be weighed and preserved along with gross lesions. Microscopic examinations of these tissues will not be conducted unless deemed necessary to interpret other observations made during the study or requested by the Sponsor (additional cost).

A.S. = All Survivors;

8 TEST MATERIAL:

8.1 TEST MATERIAL: Vinyl Chloride

Description, lot number, storage, expiration date and handling procedures, as well as other pertinent information will be documented in the study data. Properties of the test material are presented in the Appendix B.

8.2 IDENTIFICATION OF TEST MATERIAL:

Unless otherwise noted, the identity, strength, purity, composition, stability, and method of synthesis, fabrication and/or derivation of each batch of the test material will be documented by the Sponsor before its use in the study.

8.3 ANALYSIS OF THE TEST MATERIAL:

The purity of the test material at the start of study and at 6-month intervals will be determined and reported. These analyses will be performed in the analytical laboratory of the Testing Facility.

8.4 ARCHIVAL SAMPLES:

A sample (approximately 10 grams) from each lot of test material used on study will be taken and stored in the Archives of the Testing Facility at East Millstone, NJ.

8.5 UNUSED TEST MATERIAL:

At completion of the study unused test material, waste material and empty test material containers will be returned to the sponsor (information concerning where these materials should be returned will be provided by the Sponsor).

9 TEST ANIMALS:

Albino Rats (Outbred) VAF/Plus[®]

9.1 STRAIN:

Sprague Dawley - derived (CD[®])
[CrI: CD[®] BR]

9.2 SUPPLIER:

Charles River Laboratories
Portage, Michigan

9.3 JUSTIFICATION FOR TEST SYSTEM SELECTION:

The rat is a rodent animal model commonly utilized in reproduction and developmental toxicity studies as recommended in the referenced guidelines. In addition, a historical control data base with this strain of animal and supplier facility is available for comparative evaluation.

9.4 ANIMAL REQUIREMENTS/SPECIFICATIONS:

9.4.1 Number:

9.4.1.1 Two-generation Reproduction Study (P_1):

	<u>Total</u>	<u>Males</u>	<u>Females</u>
Placed on test	240	120	120

9.4.1.2 Developmental Toxicity Study:

Placed on test - 100 mated females (25/group).

9.4.2 Age:

9.4.2.1 Two-generation Reproduction Study (P_1):

Males and females: approximately four weeks at receipt; approximately six weeks (and no more than eight weeks) at initiation of treatment.

9.4.2.2 Developmental Toxicity Study:

Females: eight weeks at receipt and at least 10 weeks at initiation of mating. Females will be nulliparous and non-pregnant.

Males: in-house breeding colony used only for mating.

9.5 ACCLIMATION PERIOD:

Approximately two weeks; all animals will be checked for viability twice daily. Prior to assignment to study all animals will be examined to ascertain suitability for study.

9.6 ANIMAL HUSBANDRY:

9.6.1 Housing:

9.6.1.1 Two-generation Reproduction Study (P_1):

Animals will be housed in suspended, stainless steel cages with wire mesh fronts and floors. For the first week of acclimation, animals will be housed two/sex/cage. Thereafter, animals will be housed individually except as follows:

Mating: one male and one female co-housed nightly.

Lactation: dam with litter.

Postweaning: two littermates/sex until selection for P_2 parental generation.

During exposures, parental animals will be housed individually in suspended stainless steel wire mesh cages. Neonates will be housed 1-2/cage (littermates) until the formal initiation of the premating treatment period.

9.6.1.2 Developmental Toxicity Study:

Animals will be housed in suspended, stainless steel cages with wire mesh fronts and floors except during mating when females will be co-housed overnight with a male. During exposures, animals will be housed in suspended stainless steel wire mesh cages.

9.6.2 Food:

Certified Rodent Diet, No. 5002; (Meal) (PMI Feeds, Inc., St. Louis, MO). Each animal's cage will be fitted to retain a glass feeder cup with a stainless steel lid. Feed will be available *ad libitum* during non-exposure periods except on the evening prior to necropsy when parental animals (P_1 and P_2) will be fasted. During exposures, animals will not have access to feed.

9.6.3 Water:

Facility water supply (Elizabethtown Water Company, Westfield, NJ); without restriction, via an automated water delivery system to individual animal cages.

9.6.4 Bedding Material - Two-generation Reproduction Study:

Hardwood shaving bedding (Lab Aspen Shavings, North Eastern Products Corporation, Warrensburg, NY) will be provided for each mated female on Day 20 of gestation. Fresh bedding will be provided as needed to Day 14 of lactation.

9.6.5 Feed Analysis:

Analytical certification of batches of feed used during the study which are provided by the manufacturer, will be maintained on file at the Testing Facility. There are no known contaminants in the feed which are expected to interfere with the results of this study.

9.6.6 Water Analysis:

Monthly water analyses, provided by the supplier, will be maintained on file at the Testing Facility. Biannual chemical and microbiological analyses of water samples collected from representative rooms in this facility will be conducted to assure that water being provided meets standards specified under the EPA National Primary Drinking Water Regulations (40 CFR Part 141). Results will be maintained on file. There are no known contaminants in the water which are expected to interfere with the results of this study.

9.6.7 Bedding Analyses:

Analyses for each batch of bedding used on study provided by the supplier, will be maintained at the Testing Facility. There are no known contaminants in the bedding which are expected to interfere with the results of this study.

9.6.8 Veterinary Care:

Animals will be monitored by the technical staff for any conditions requiring possible veterinary care. If any such conditions are identified, a staff veterinarian will be notified for an examination and evaluation. Any medical veterinary intervention will be made only with approval of the staff veterinarian and the Study Director. The Sponsor will be consulted whenever possible. However, in emergency situations, decisions will be made as needed and the Sponsor will be advised as soon as possible.

9.6.9 Environmental Conditions:

9.6.9.1 Light/Dark Cycle:

Twelve hour light/dark cycle daily.

9.6.9.2 Temperature:

Monitored and recorded twice daily. Temperature in the animal room will be maintained in the range of approximately 20-24°C to the maximum extent possible.

9.6.9.3 Humidity:

Monitored and recorded once daily. The desired humidity range is 40-70%. Humidity will be maintained in this range to the maximum extent possible.

9.7 SELECTION FOR STUDY:

9.7.1 Two-generation Reproduction Study (P₁) :

More animals than required for the study will be purchased and acclimated. Animals considered suitable for study on the basis of pretest physical examinations, body weight data and any other pretest evaluations will be randomly assigned to control or treated groups in an attempt to equalize mean group body weights. Individual weights of animals placed on test shall not exceed 20% of the mean weight for each sex. Disposition of all animals not used in the study will be maintained in the study file.

9.7.2 Developmental Toxicity Study:

More females than required for the study will be purchased and acclimated. Animals considered suitable for study on the basis of pretest physical examinations will be included into the mating phase of the study. Females which mate will be assigned to groups daily in such a way as to most nearly equalize both the Day 0 mean body weights between groups and the distribution of animal into groups.

9.8 ANIMAL IDENTIFICATION:

9.8.1 Two-generation Reproduction Study:

Each animal will be assigned a temporary identification number upon receipt. After selection for study (P₁ generation), each animal will be ear-tagged with a number assigned by the Testing Facility.

9.8.1 Two-generation Reproduction Study:

This number plus the study number will comprise the unique identification for each study animal. Following the procedure (post-weaning) to select the P_2 parental animals from the F_1 offspring, these selected animals will be ear-tagged with a unique number. If the tag is lost, it will be replaced or the animal will be tail tattooed for identification. Each animal's cage will be provided with a card which will be color-coded for dose level identification and will contain the study number and animal number.

9.8.2 Developmental Toxicity Study:

Each female will be assigned a temporary identification number upon receipt. Mated females sorted into study groups will be ear-tagged with a number assigned by the Testing Facility that will be unique from the identification numbers used in the two-generation study. This number plus the study number will comprise the unique identification for each study animal. Females will be eartagged on Day 0 of gestation.

10 MATING, GESTATION AND LACTATION PROCEDURES:

10.1 MATING PROCEDURE:

10.1.1 Two-generation Reproduction Study (P_1 , P_2):

After animals have been exposed to the test substance for the appropriate length of time (pre-mating treatment period), one male and one female of equivalent dose levels will be caged together nightly until a sign of mating (microscopic observation of sperm in the vaginal smear and/or a copulation plug in the vagina) is observed or for 14 consecutive days. The day evidence of mating is observed will be defined as Day 0 of gestation. If mating has not occurred after this interval, the animals will be separated without further opportunity for mating. During mating of the P_2 generation cohabitation of male and female littermates will be avoided.

10.1.2 Developmental Toxicity Study:

Females selected for mating will be placed with breeder males nightly in a 1:1 ratio. Vaginal smears will be taken early in the morning following nightly interval of co-housing and females will be considered to have mated if sperm is observed microscopically in the vaginal smear and/or a vaginal plug is observed. The day on

10.1.2 Developmental Toxicity Study:

which evidence of mating is observed will be defined as Day 0 of gestation.

10.2 PARTURITION AND LACTATION - TWO-GENERATION REPRODUCTION STUDY:

On Day 20 of gestation, several days prior to expected parturition, each mated female's cage will be fitted to retain a stainless steel floor pan and bedding material provided. Examination for signs of parturition will be made twice daily (morning and afternoon). Evidence of difficult or prolonged parturition, if observed, will be recorded. The day on which all pups have been delivered will be defined as Day 0 of lactation. For females which were caged with males but exhibited no evidence of mating, preparations for undetermined pregnancies (i.e., floor pan, bedding material) will be made when the first animals mated reach their day 20 of gestation.

10.3 SELECTION OF P_2 PARENTAL GENERATION:

At weaning of each F_1 litter, two pups/sex/litter will be chosen at random to become a pool of animals from which the P_2 parental generation will be selected. Pups as chosen will be housed two littermates of the same sex/cage. After weaning of the last F_1 litter, 30 F_1 pups/sex/group will be selected from this pool of animals to become the P_2 parental animals. In this selection procedure, each litter will contribute at least one pup/sex, when possible, so as to maximize the representation of animals from different litters in each group.

After the last litter is weaned, the 30 F_1 pups/sex/group designated for the P_2 parental generation will formally initiate the premating treatment period. Thus, there may be a maximum of two weeks difference in age for the P_2 animals within each treatment group at initiation of the premating growth period. During this postweaning period, the pool of F_1 pups will be chambered and exposed (6 hrs./day) at the treatment level of the dam.

In the selection procedure, grossly malformed or obviously-diseased animals within the litters will be excluded from the pool of animals eligible for selection if, in the judgement of the Study Director, their condition may adversely affect long-term survival. Runts, if otherwise normal, will not be excluded from the selection procedure.

11 TEST MATERIAL ADMINISTRATION:

11.1 ROUTE OF ADMINISTRATION:

Inhalation (whole body).

11.2 JUSTIFICATION FOR ROUTE OF ADMINISTRATION:

The inhalation route is one of the potential routes of human exposure to this test material.

11.3 FREQUENCY OF ADMINISTRATION:

11.3.1 Two-generation Reproduction Study:

P₁ and P₂ generation animals will be exposed 6 hours/day, five days/week for at least 70 days (10-week) prior to mating (designated the premating treatment period). Males will continue to be exposed daily, 6 hrs/day during the 14-day mating period and postmating period until sacrificed. Females will continue to be treated daily, 6 hrs/day during mating and mated females will continue to be treated, 6 hrs/day during the ensuing gestation period through to Day 20. Females will be allowed to deliver (Day 0 of lactation) and initiate lactation and treatment will resume on Day 4 of lactation. Females will continue to be treated (6 hrs/day) thereafter for the remainder of lactation and postweaning period until sacrificed. Unmated females will continue to be treated daily (6 hrs/day) until sacrificed.

11.3.2 Developmental Toxicity Study:

Females will be treated 6 hours/day over the Day 6-19 gestation interval. The exposure interval for these animals will coincide with the exposures for the mating/gestation/lactation periods for the F₁ litters in the two-generation reproduction study.

11.4 GENERATION PROCEDURE:

The test material will be administered as a vapor/aerosol in the breathing air of the animals. The test atmospheres will be generated by an appropriate procedure to be developed at the Testing Facility. The generation method will be described in the final report and maintained with the data package for this study.

The whole-body exposure chambers will have a minimum volume of approximately 6000 liters (6 m³). Each chamber will be operated at a minimum flow rate of 1200 liters per minute. The final airflow will be set

11.4 GENERATION PROCEDURE:

to provide at least one air change in 5.0 minutes (12 air changes/hour) and a T_{99} equilibrium time of approximately 23 minutes. This chamber size and airflow rate are considered adequate to maintain the oxygen level above 19%.

11.5 CHAMBER MONITORING:

A nominal exposure concentration will be calculated, if possible. The flow of air through the chamber will be monitored using appropriate calibrated equipment. The test material consumed during the exposure will be divided by the total volume of air passing through the chamber (volumetric flow rate times total exposure time) to give the nominal concentration.

During each test material exposure, measurements of airborne concentrations will be made at least hourly using a MIRAN infrared spectrophotometer. Also prior to initiating of animal exposures, additional samples will be taken to determine the distribution of the test material in the exposure chamber.

If more than the normal amount of trialing is required because of test material generation or monitoring problems (two weeks or 150 technician hours), the Sponsor will be consulted prior to additional trialing (additional cost).

The minimum frequency of chamber activity is summarized below:

Activity	Frequency/chamber/day
Analytical Test Material Concentration	6 times (hourly)
Temperature	12 times
Relative Humidity	12 times
Airflow Rate	12 times
Nominal Test Material Concentration (excluding the control chamber)	once
Rotation Pattern of Exposure Cages	once
Loading/Unloading Verification	once

11.6 EXPOSURE CONCENTRATIONS:

For both the two-generation reproduction and developmental toxicity studies the targeted exposure concentrations will be 0, 10, 100 and 1100 ppm of the test material. These exposure levels correspond to oral equivalent doses of approximately 0, 9.2, 92 and 1012 mg/kg/day assuming ventilation rates of 1 L/min/kg, 100 percent absorption and a 6 hr/day exposure. The high concentration of vinyl chloride was selected based on the oral equivalent of the limit dose of 1000 mg/kg body weight/day. The high exposure level of 1100 ppm is also expected to produce effects on the liver and other organ systems (ATSDR, 1993). The middle and low exposure levels were selected to provide a dose response for the observed effects and a no-observed-effect level, respectively.

12 EXPERIMENTAL EVALUATIONS:

12.1 OBSERVATIONS:

12.1.1 Viability Checks - Two-generation reproduction study and developmental toxicity study:

Observations for mortality, general appearance and signs of severe toxic or pharmacologic effects as well as availability of feed and water will be made at least twice daily (morning and afternoon). Animals in extremely poor health or in a possible moribund condition will be identified for further monitoring and possible euthanasia. All animals found dead will be submitted for a gross macroscopic examination. Parental animals found dead after normal working hours will be refrigerated until a necropsy can be performed.

12.1.2 Physical Examinations:

12.1.2.1 Two-Generation Reproduction Study:

Each animal will be removed from its cage and examined at least once pretest (P_1), at the study start (first day of treatment for the P_1) and weekly thereafter during the study period (P_1 and P_2). Examinations will include observations of general condition, skin and fur, eyes, nose, oral cavity, abdomen and external genitalia as well as evaluations of respiration, and palpation for tissue masses. These examinations will be performed postexposure when animals are being transferred to their home cages.

12.1.2.2 Developmental Toxicity Study:

Mated animals will be given a detailed physical examination on Days 0 and 6-20 (daily) of gestation. Examinations will include observations of general condition, skin and fur, eyes, nose, oral cavity, abdomen and external genitalia as well as evaluations of respiration, and palpation for tissue masses. During the test period, these examinations will be performed postexposure when animals are being transferred to their home cages.

12.2 BODY WEIGHTS:

12.2.1 Two-generation Reproduction Study:

Males:

P₁: at the time of sorting into groups, on the day treatment initiates, weekly throughout the study and at termination.

P₂: at the formal initiation of the premating treatment period and weekly throughout the study and at termination.

Females:

P₁: at the time of sorting into groups.

P₁ and P₂: on the day treatment initiates (formal initiation of the premating period for the P₂), weekly during the premating growth periods; gestation - Days 0, 7, 14 and 20; and lactation: days 0, 4, 7, 14, 21 and 25 (P₁ only); and at termination.

12.2.2 Developmental Toxicity Study:

Females will be weighed on Days 0, 6, 9, 12, 15 and 20 of gestation.

12.3 FOOD CONSUMPTION:

12.3.1 Two-generation Reproduction Study:

Males:

P₁: one week pretest.

P₁ and P₂: weekly during the premating treatment period and from termination of mating through to sacrifice (postmating period). Food consumption will not be recorded during the mating periods.

Females:

P₁: one week pretest.

P₁ and P₂: weekly during the premating period; during gestation - Days 0-7, 7-14 and 14-20; during lactation - Days 1, 4, 7, 10 and 14. Food consumption will not be recorded during the mating period or postweaning period prior to termination.

12.3.2 Developmental Toxicity Study:

Food consumption will be recorded for the following intervals during Gestation: Days 0-6, 6-9, 9-12, 12-15 and 15-20.

12.4 ESTROUS CYCLE DETERMINATIONS - TWO-GENERATION REPRODUCTION STUDY:

Estrous cycle length and normality will be evaluated daily by vaginal lavage on the first 15 P₁ and P₂ females per group for the three week period prior to mating and continuing throughout the mating period or until the female is confirmed mated.

12.5 LITTER EVALUATIONS (F₁, F₂) - TWO-GENERATION REPRODUCTION STUDY:

12.5.1 Observations:

Litters will be observed as soon as possible after delivery for the number of live and dead pups and pup abnormalities (Day 0 of lactation). Thereafter, litters will be observed twice daily (morning, afternoon) for the presence of dead pups. These pups and pups euthanized in a moribund condition will be examined to the extent possible for defects and/or cause of death and preserved in neutral, phosphate-buffered 10% formalin. Litter size will be recorded on Days 0, 4, 7, 14, 21 (F₁ and F₂) and 24 (F₁ only) of lactation.

12.5.2 Culling:

On Day 4 of lactation, each litter with more than eight pups will be culled to that number with sex distribution equalized (four/sex) when possible. Pups will be culled using a random number table. Preferential culling of runts will not be performed. Culled pups will be examined grossly for abnormalities and following euthanasia by an overdose of inhaled carbon dioxide (CO₂) will have sex confirmed by internal inspection of the gonads. Only culled pups with abnormalities will be preserved in 10% neutral buffered formalin.

12.5.3 Physical Examinations:

Each pup will be given a gross physical examination on Days 0, 4, 7, 14, 21 and 24 (F₁ pups only).

12.5.4 Pup Body Weights and Sexing Data:

Individual pup weights and pup sexing data will be recorded on Days 0, 4 (presented for both pre- and postcull intervals), 7, 14, 21 and 24 (F₁ pups only) of lactation.

12.5.5 Physical Maturation Landmarks - Selected P₂ Animals:

All F₁ weanlings selected to become the P₂ parental animals (30 sex/group) will be observed daily for vaginal opening beginning on postnatal day 30 or preputial separation beginning on postnatal day 35. If a treatment-related effect is seen in F₁ sex ratios, age of vaginal opening or preputial separation, then anogenital distance will be measured on postnatal day 4 for all F₂ pups.

13 POSTMORTEM:

13.1 TWO-GENERATION REPRODUCTION STUDY:

13.1.1 GROSS POSTMORTEM EXAMINATION:

13.1.1.1 Parental animals:

Complete macroscopic postmortem examinations will be performed on all adult animals, including animals euthanatized in a moribund condition or found dead. These evaluations will be performed under the direct supervision of a veterinary pathologist. The eyes of the parental animals will be examined *in situ* by gently pressing a moistened glass slide against the cornea and observing the eyes under fluorescent light. During the gross postmortem examination all abnormal observations will be recorded. The necropsy of the

13.1.1.1 Parental animals:

parental animals will include examination of the external surface and all orifices; the external surfaces of the brain and spinal cord; the organs and tissues of the cranial, thoracic, abdominal and pelvic cavities and neck; and the remainder of the carcass. Examination of all parental females which were exposed to males, will include a count of uterine implantation scars, if present.

13.1.1.2 Weanling Pups (F_1 and F_2):

At weaning (Day 24 - F_1 and Day 21 - F_2) one pup/sex/litter/group will be selected at random for a complete gross postmortem examination. These examinations will be performed under the supervision of a veterinary pathologist. To control for variation in body weight and organ weight, all pups will be sacrificed at the same age.

13.1.2 TIME OF NECROPSY:

13.1.2.1 Moribund Animals:

Animals showing signs of severe debility, particularly if death appears imminent, will be euthanatized to prevent loss of tissues through autolysis.

13.1.2.2 Terminal Necropsy Males (P_1 , P_2):

P_1 males will be sacrificed after the last F_1 litters have been delivered. This will permit some evaluation of fertility (i.e., number of litters delivered) prior to sacrifice. The P_2 males will be sacrificed approximately one week after completion of the mating period to produce the F_2 pregnancies. The Sponsor will be notified prior to sacrifice of the P_1 and P_2 males.

13.1.2.3 Terminal Necropsy Females (P_1 , P_2):

All P_1 and P_2 females, regardless of reproductive status (unmated, mated but not pregnant, or with litter) will be sacrificed as a group after the last litters have weaned for all groups. Parental females (P_1 and P_2) will be necropsied on day 2 of diestrus whenever possible. This will be identified by daily vaginal smearing of the females for the occurrence of at least one estrous cycle after which time females found to be in day one of diestrus will be fasted overnight and necropsied the following day. The presence of diestrus will be confirmed by vaginal smearing the morning of necropsy.

13.1.2.4 Terminal Necropsy Pups (F_1 , F_2):

13.1.2.4.1 Dead and Culled Pups:

Pups found dead at birth or during the lactation period will be examined to the extent possible for defects and/or the cause of death, presence or absence of milk in the stomach. Dead pups will not be eviscerated. Viscera will remain intact and the pup will be preserved in 10% neutral buffered formalin. Cannibalized pups will be examined to the extent possible and discarded. Culled pups will be examined for external irregularities, sexed internally to confirm external sexing and if unremarkable these pups will be discarded. Culled pups with external irregularities will be preserved intact in 10% neutral buffered formalin.

13.1.2.4.2 Unselected F_1 Pups:

Pups selected as a pool of animals from which the P_2 parental animals will be selected but which were not identified to continue on study, will be given an external examination and if unremarkable, sacrificed and discarded. Pups with external findings will be given a gross internal examination and only abnormal tissues taken and preserved in 10% neutral buffered formalin. Remaining pups in each litter will be given a gross external examination at weaning and if unremarkable, sacrificed and discarded. Pups with external findings will be given a gross internal examination and only abnormal tissues taken and preserved in 10% neutral buffered formalin.

13.1.2.4.3 Unselected F_2 Pups:

At weaning, unselected F_2 pups in each litter will be given a gross external examination and if unremarkable, sacrificed and discarded. Pups with external findings will be given a gross internal examination and only abnormal tissues taken and preserved in 10% neutral buffered formalin.

13.1.3 METHOD OF EUTHANASIA:

13.1.3.1 Parental Animals:

Exsanguination following anesthesia with inhaled carbon dioxide.

13.1.3.2 Weanlings:

Weanling pups selected for a complete gross postmortem examination will be sacrificed by exsanguination following anesthesia with inhaled carbon dioxide. Remaining pups will be sacrificed with an overdose of inhaled carbon dioxide.

13.1.4 Organ Weights:

13.1.4.1 Parental Animals:

The following organs will be weighed at terminal sacrifice from the first 15 P₁ and P₂ animals in each group:

uterus	ovaries
testes	right epididymis (total and cauda)
seminal vesicles (with coagulating glands and their fluids)	prostate
brain	liver
kidneys	lungs
adrenals	spleen
thymus	

13.1.4.1 Parental Animals:

Organ weight data will be presented as absolute values and relative to terminal body weight. Organ weights will not be recorded for animal dying spontaneously or sacrificed moribund.

13.1.4.2 Weanling Pups (F₁ and F₂):

The following organs will be weighed from the first 15 male and female pups per group selected for complete macroscopic examination at weaning:

ovaries	testes
brain	liver
kidneys	adrenals
spleen	thymus

Organ weight data will be presented as absolute values and relative to terminal body weight.

13.1.5 TISSUES PRESERVED:

13.1.5.1 Parental Animals:

Grossly abnormal tissues will be preserved for all parental animals. Tissues listed in Appendix A will be obtained at necropsy and preserved for all P₁ and P₂ parental animals.

13.1.5.2 Weanling Pups:

Grossly abnormal tissues and tissues listed in Appendix A will be preserved for all F₁ and F₂ weanling pups selected for complete gross macroscopic examination.

13.1.6 Preservatives:

All tissues - 10% neutral buffered formalin. Testes and epididymides of the parental animals will be fixed in Bouin's solution for at least 48 hrs prior to permanent storage in formalin. Lungs will be infused with formalin to their approximate normal inspiratory volume. The nasal cavity will be flushed with formalin via the pharyngeal duct to ensure rapid fixation of the tissue.

13.1.7 MICROSCOPIC PATHOLOGY EVALUATIONS:

Slides of tissues listed in Appendix A (under Microscopic Examination) will be prepared and examined microscopically for all P₁ and P₂ animals in the control and high-dose groups. If microscopic findings indicative of an effect of test material administration are seen in high-dose animals, then examinations will be made of these tissues/organs for low- and mid-dose animals (additional cost). Additional examinations will be made only after consultation with the Sponsor and receipt of authorization from the Sponsor. Note: any abnormalities not noted during macroscopic postmortem examinations which are seen during histological processing will be recorded. Gross lesions will be examined at additional cost.

13.1.8 STAINS:

Standard stains used, hematoxylin and eosin. Special stains may be employed on selected tissues to aid in making a diagnosis at the discretion of the Study Pathologist. Special stains may be employed at the request of the Sponsor (additional cost).

13.1.9 SPERM COUNT, MOTILITY AND MORPHOLOGY ASSESSMENTS:

From the first 15 P₁ and P₂ parental males sacrificed at termination in each group, samples of sperm from the vas deferens (left) and distal cauda epididymis (left) will be collected. Motility will be assessed on sperm collected from the vas deferens and a count will be performed on the sperm sample collected from the cauda epididymis. A manual procedure developed in the testing facility will be used to assess motility and perform the count. Additionally, a slide of the sperm sample from the cauda epididymis will be prepared for morphological assessment if deemed necessary (Sponsor decision - additional cost item).

13.2 DEVELOPMENTAL TOXICITY STUDY:

13.2.1 MATERNAL TERM SACRIFICES:

Macroscopic postmortem examinations will be performed on all mated rats, including those dying spontaneously or killed in a moribund condition and on females sacrificed after aborting or premature delivery of a litter. The livers and kidneys will be weighed and preserved in 10% neutral buffered formalin for all females killed on Day 20 of gestation but microscopic examinations of these tissues will not be conducted unless deemed necessary to interpret other observations made during the study or as requested by the sponsor (additional cost item). Gross lesions identified

13.2.1 MATERNAL TERM SACRIFICES:

during the macroscopic evaluations will be saved in 10% formalin. Dams showing signs of abortion or premature delivery (expulsion of concepti) will be killed (overdose of inhaled carbon dioxide) on the day such evidence is observed. Reproductive tracts will be examined and fetuses obtained 19 days or later will be given an external examination, eviscerated and processed for skeletal staining with Alizarin Red S. These fetuses will then be examined for skeletal malformations. Fetuses obtained earlier than Day 19 will be evaluated for external malformations and saved (10% neutral buffered formalin) at the discretion of the Study Director. Examination data for these fetuses (Day 19 of gestation or earlier) will not be analyzed with data for term Day 20 gestation fetuses. Data for these fetuses will be presented in a separate appendix to the final report.

13.2.2 Reproductive System:

The intact uteri (ovaries attached) will be removed from the abdominal cavity and weighed. This uterine weight data will then be used to calculate a corrected Day 20 gestation body weight for each animal. The corrected Day 20 gestation weight will be determined by subtracting the gravid uterine weight from the terminal Day 20 gestation weight. Each uterine horn will then be evaluated for the number and location of the following:

- live fetuses (movement in response to touch);
- dead fetuses (lack of movement in response to touch but with no visible degeneration);
- late resorptions (recognizable dead fetus undergoing degeneration, regardless of size);
- early resorptions (evidence of implantation but no recognizable fetus);
- implantation sites (total of fetuses plus resorptions).

Ovaries: corpora lutea will be counted for each ovary.

Uteri without grossly visible implantations will be stained with ammonium sulfate (Salewski, 1964). If stained foci are present, the female will be considered pregnant for purposes of calculating pregnancy rates. The number of foci will not be used in the calculation of uterine implantation data.

13.2.3 Fetal evaluations:

13.2.3.1 External Evaluations:

All fetuses will be weighed and individually identified. Each fetus will be given a gross external examination for defects to include observation of the palate. The sex of each fetus will be noted by observation of the anogenital distance.

13.2.3.2 Fetal Skeletal Evaluations:

Approximately one-half of the fetuses in each litter (alternating fetuses within the litter) will be processed for Alizarin Red S staining of the skeletal structures. Prior to processing, the intact fetuses will be killed (overdose of inhaled carbon dioxide) and eviscerated (internal sex noted). Following staining, these fetuses will be evaluated for skeletal malformations and ossification variations.

13.2.3.3 Fetal Soft Tissue Evaluations:

The remaining fetuses in each litter will be processed for soft tissue examination using a microdissection technique similar to the procedure of Staples (1974). The evaluations will be performed on the fresh fetal specimens soon after removal from the uterus. The fetuses designated for soft tissue evaluation will be decapitated (head placed in Bouin's solution for later evaluation). The fetal specimens will then be secured beneath a dissecting microscope and dissected so as to permit evaluation of tissues in the thoracic, abdominal and pelvic cavities. At completion of the examination, the decapitated fetal specimens will be eviscerated and processed for Alizarin Red S staining. These fetuses will not be evaluated skeletally unless authorized by the sponsor (additional cost).

Fetal heads, preserved in Bouin's solution, will be sectioned with a razor blade. The serial, transverse sections generated during this procedure will be evaluated for malformations of the palate, eyes and brain.

Fetal soft tissue and skeletal evaluations (microdissection, stained specimens and head sections) will be performed under a dissecting microscope.

13.2.4 Resorptions:

Late resorptions will be examined externally for malformations. Malformation data for late resorptions will be reported but not included in the analyses of malformation data for live or dead

13.2.4 Resorptions:

fetuses recovered on Day 20 of gestation. Only late resorptions with external malformations will be saved (10% neutral buffered formalin) for future possible examination. Early resorption will be discarded.

14 PRESERVATION OF RECORDS AND SPECIMENS:

All data documenting experimental details and study procedures and observations will be recorded and maintained as raw data.

At the completion of the study, all reports, raw data, preserved specimens and retained samples will be maintained in the Testing Facility's Archives for a period of five years after submission of the signed final report.

The Sponsor will be contacted in order to determine the final disposition of these materials. The Sponsor is responsible for all costs associated with the storage of these materials beyond one year from the issuance of the final report and for any costs associated with the shipment of these materials to the Sponsor or to any other facility designated by the Sponsor.

15 STATISTICAL EVALUATIONS:

The following items will be analyzed statistically in the final report:

15.1 CONTINUOUS DATA:

15.1.1 Two-generation Reproduction Study:

Mean body weights (all recorded intervals - pre mating, gestation, lactation and post mating);

Mean body weight change;

- entire pre mating period (males and females) - Weeks 0-10;
- over each weighing interval during the gestation and lactation periods to include Days 0-20 of gestation and Days 0-24 (F₁ litters) or Day 0-21 (F₂) of lactation;
- males during the post mating period (weekly and over the entire period).

Mean food consumption values;

- pre mating growth period (weekly);
- post mating period (weekly for males);
- gestation (Days 0-7, 7-14, 14-20);
- lactation (all recorded intervals);

15.1.1 Two-generation Reproduction Study:

Organ weight data (absolute and relative to the terminal body weight);
Mean pup weights (all recorded intervals during lactation);
Mean number of pups (live, dead, total) at birth (F_1 and F_2 litters);
Mean gestation length (F_1 and F_2 litters);
Mean pup live birth indices (F_1 and F_2 litters);
Mean pup viability indices (Days 0-4) and weaning indices (Days 4-24 or 21 for the F_1 and F_2 litters, respectively);
Mean age-to-criteria for vaginal opening and preputial separation (P_2 animals);
Mean sperm count and motility data.

15.1.2 Developmental Toxicity Study:

Mean maternal body weights (all recorded intervals during gestation) and weight gain (between all weighing intervals to include Days 6-20 of gestation using both the actual and corrected Day 20 gestation weight);
Mean organ weight data, absolute and relative to the corrected Day 20 gestation weight;
Mean number of corpora lutea, implants, live and dead fetuses, resorptions per pregnant female;
Mean pre- and post-implantation loss indices;
Mean fetal weights (distinguished by sex and as a composite for both sexes);

15.1.3 STATISTICAL ANALYSES CONTINUOUS DATA - MULTIPLE GROUP ANALYSES:

Data will be compared between the sham, chamber-housed control and the treated groups.

Statistical evaluation of equality of means will be made by the appropriate one way analysis of variance technique, followed by a multiple comparison procedure if needed. Bartlett's test will be performed to determine if groups have equal variance. If the variances are equal ($p > 0.01$), parametric procedures will be used; if not ($p < 0.01$), nonparametric procedures will be used. The parametric procedures will be the standard one way ANOVA using the F distribution to assess significance. If significant differences among the means are indicated, Dunnett's test will be used to determine which means are significantly different from the control. If a nonparametric procedure for testing equality of means is needed, the Kruskal-Wallis test will be used, and if differences are indicated, a

15.1.3 STATISTICAL ANALYSES CONTINUOUS DATA - MULTIPLE GROUP ANALYSES

summed rank test (Dunn) will be used to determine which treatments differ from control.

A statistical test for trend in the dose levels will also be performed. In the parametric case (i.e., equal variance), standard regression techniques with a test for trend and lack of fit will be used. In the non-parametric case, Jonckheere's test for monotonic trend will be used.

The test for equal variance (Bartlett's) will be conducted at the 1% two-sided risk level. All other statistical tests will be conducted at the 5% and 1%, two-sided risk levels.

All ratios (pup survival indices, pre- and postimplantation loss indices) will be transformed via Bartlett's transformation followed by the arc-sine transformation prior to analysis. Data will be presented untransformed.

References for these techniques are Snedecor, G.W., Cochran, W.G., *Statistical Methods*, 6th edition, Iowa State Univ. Press (1967); Hollander and Wolfe, *Nonparametric Statistical Methods*, John Wiley and Sons, New York (1973); Dunnett, C.W., *J. Am. Sta. Assn.* 50: 1096-1121 (1955) and *Biometrics* 20: 482 (1964).

Bartlett's Test	pp. 296-298	Snedecor & Cochran
ANOVA	pp. 277-279	Snedecor & Cochran
Dunnett's Test	pp. 1096-1121	Dunnett
	pp. 482-491	Biometrics
Kruskal-Wallis	pp. 114-116	Hollander & Wolfe
Summed Rank Test (Dunn)	p. 131	Hollander & Wolfe
Arc Sine Transformation	pp. 327-329	Snedecor & Cochran
Bartlett's transformation	p. 329	Snedecor & Cochran
Regression Analysis - Trend	pp. 135-153	Snedecor & Cochran
Lack of fit	pp. 456-459	Snedecor & Cochran
Jonckheere's Statistic	pp. 120-123	Hollander & Wolfe

15.2 INCIDENCE DATA:

15.2.1 Two-generation Reproduction Study:

Mortality rates;
Mating indices (male and female);
Pregnancy rates;
Male fertility indices;
Litter survival indices;

15.2.2 Developmental Toxicity Study:

Maternal Mortality
Pregnancy rates
Incidence of females with resorptions;
Incidence of fetuses with malformations/variations - external, soft tissue and skeletal examinations;
Incidence of litters containing fetuses with malformations/variations -external, soft-tissue and skeletal.

15.2.3 INCIDENCE DATA ANALYSIS:

Data will be compared between the sham, chamber-housed control and the treated groups.

Statistical analysis of incidence data will be performed using contingency tables. First, a standard Chi-square analysis will be performed to determine if the proportion of incidences differed between the groups tested. Next, each treatment group will be compared to the control group using a 2 x 2 Fisher Exact Test; the significance level will be corrected via the Bonferroni inequality to assure an overall test of the stated significance level. Thirdly, Armitage's test for linear trend in the dosage groups will be performed. In keeping with standard statistical practice, if any one cell has an expected value less than 5, the Chi-square and Armitage's tests will not be reported. When this occurs, only the Fisher Exact test (corrected via Bonferroni inequality) will be performed and reported.

All tests will be reported at the 5% and 1% level of significance.

15.2.3 INCIDENCE DATA ANALYSIS:

References for the techniques are Snedecor, G.W., and Cochran, W.G., *Statistical methods*, 6th ed., Iowa State University Press, Ames, Iowa (1971); Bradley, J.V., *Distribution Free Statistical Tests*, Prentice-Hall, Englewood Cliffs, New Jersey (1968); Miller, R.G., Jr., *Simultaneous Statistical Inference*, McGraw-Hill Book Co., New York (1966); Armitage, P., "Tests for Linear Trends in Proportions and Frequencies", *Biometrics*, (Sept. 1955).

Chi-square	pp. 250-253	Snedecor & Cochran
Fisher Exact Test	pp. 195-203	Bradley
Bonferroni Inequality	p. 15	Miller
Armitage's Test	pp. 375-386	Armitage

16 REFERENCES:

ATSDR, (1993). Toxicology Profile for Vinyl Chloride. U.S. Department of Health and Human Services. Public Health Services. Agency for Toxic Substances and Disease Registry.

EEC (1988). European Economic Community. Methods for the Determination of Toxicity. Official Journal of the European Communities, Vol.31, No.. L133, 30 May 1988. ISSN 0378-6978.

EPA (1985). Environmental Protection Agency Toxic Substances Control Act Test Guidelines, Final Rule. 40 CFR Part 798, 27 September 1985, pp. 39426-39433.

EPA (1990). Environmental Protection Agency Toxic Substances Control Act; Good Laboratory Practice Standards. 40 CFR Part 792 (1 July 1990).

FDA (1988). Food and Drug Administration Good Laboratory Practice for Nonclinical Studies. 21 CFR Part 58 (1 April 1988).

OECD (1981). Organisation for Economic Co-Operation and Development Guidelines for Testing of Chemicals, Section 4 - Health Effects, Paris.

OECD (1982). Organisation for Economic Co-Operation and Development, Principles of Good Laboratory Practice, ISBN 92-64-12367-9, Paris.

Plowchalk, D.R., Smith, B.J. and Mattison, D.R. (1993). Assessment of toxicity of the ovary using follicle quantitation and morphometrics. In Methods in Toxicology, Vol.3, Part B, Female Reproductive Toxicology. (J. J. Heindel and R.E. Chapin, Eds.). Academic Press, Inc., New York, NY.

16 REFERENCES:

Salewski, E. (1964). Farbemethode zum makroskopischen nachweis von implantationsstellen am uterus der ratte. *Archiv. Path. Exp. Pharmacol.*, 247:367

Staples, R. E. (1974). Detection of Visceral Alterations in Mammalian Fetuses. *Teratology*, 9:37 (Abstract).

17 REPORT:

17.1 STATUS REPORT:

For the two-generation reproduction study, status reports will be issued monthly during the premating treatment period and after weaning of the F₁ and F₂ litters. In the developmental toxicity study a status report will be submitted after the last Day 20 gestation maternal sacrifices. These reports will include:

Two-generation Reproduction Study:

Mortality rates

Mean weekly body weight and weight gain data;

Mean weekly food consumption premating period;

Summary of detailed physical examinations;

Mating indices (males and females);

Male fertility indices;

Pregnancy rates;

Gestation length;

Number of pups at birth (live, dead and total) and number of live pups surviving during lactation;

Mean pup weights (lactation);

Individual female litter data (F₁, F₂);

Maternal gestation body weights and weight gains;

Maternal food consumption - gestation/lactation;

Summary of gross postmortem evaluations (adults, weanlings)

Developmental Toxicity Study:

Mortality rates:

Mean body weight and weight gain data during gestation;

Mean food consumption data;

Summary of detailed physical examination data;

Mean corpora lutea and uterine implantation data;

17.1 STATUS REPORT:

Mean number of live and dead fetuses and resorptions per pregnant female;
Mean pre- and post-implantation loss indices;
Incidence of females with resorptions;
Mean fetal weights;
Fetal external examination data;
Individual maternal Day 20 gestation sacrifice data;
Maternal organ weight data;
Summary of maternal gross postmortem examination data.

17.2 FINAL REPORT:

One copy of a draft report will be submitted following termination of the study. After receipt and review of the Sponsor's comments, appropriate changes will be made and two copies of a signed, final report will be issued. (Additional copies will be provided at additional cost). The report will include but not be limited to the following:

17.2.1 General:

Compliance Statement;
Abstract;
Introduction;
Experimental Design;
Materials and Methods;
Discussion of study results;
Conclusion and No Observed Effect Level (NOEL) statement;
Inhalation Exposure Report;
References for experimental methodology;
Senior personnel participating in the study;
Quality Assurance Statement.

17.2.2 Data tabulations for parental generations (P₁, P₂):

Mortality - termination history;
Physical in-life observations (summarized and individual data presented monthly throughout the study);
Mating indices;
Pregnancy rates;
Male fertility indices;
Mean body weight data (all interval);
Mean food consumption data (all intervals);
Mean weight gain data (prematuring, postmaturing [males], gestation and lactation intervals);
Statement on estrous cycle data;

17.2.2 Data tabulations for parental generations (P_1 , P_2):

Macroscopic postmortem observations (adults, weanlings);
Microscopic pathology examinations;
Organ weight data;
Sperm assessment data.

17.2.3 Data tabulations for litters and offspring (F_1 and F_2):

Mean gestation length;
Mean number of pups (live, dead and total) at birth and live pups at
Days 4, 7, 14 and weaning (Day 24 - F_1 and Day 21 - F_2);
Litter survival indices;
Pup live birth index;
Pup viability and weaning indices;
Mean pup weights (all recorded intervals during lactation);
Pup sex ratio at birth, Day 4 (pre- and postcull) and weaning;
Pup gross postmortem observations;
Individual female litter data.

17.2.4 Data tabulation for the developmental toxicity study:

Maternal mortality
Maternal body weight and weight gain data;
Maternal food consumption;
Physical observation data;
Pregnancy rates;
Mean number of corpora lutea and uterine implantations;
Mean number of live and dead fetuses;
Mean pre- and post-implantation loss indices;
Mean number of resorptions;
Incidence of females with resorptions;
Types of findings and incidence of fetuses with external, soft tissue
and skeletal malformations/variations;
Incidence of litters containing fetuses with malformations/variations
(external, soft tissue and skeletal)
Mean fetal weights;
Fetal sex distribution ratios;

17.2.5 Appendices:

All individual animal data (adults, pups, weanlings and fetuses)
including but not limited to the following will be presented in the
appendices: body weight and weight gain, food consumption,
physical observation data, litter and uterine implantation data, organ
weight data, sperm assessment data, estrous cycle data, gross

17.2.5 Appendices:

postmortem findings, microscopic examination data, chamber exposure data.

18 SIGNATURES:

18.1 INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC):

The IACUC Protocol Review Subcommittee has reviewed this protocol and found it to be in compliance with all appropriate regulations.

BY: _____ DATE: _____

TITLE: Institutional Animal Care and Use Committee Member

BY: _____ DATE: _____

TITLE: Institutional Animal Care and Use Committee Member
FOR: Huntingdon Life Sciences
East Millstone Facility

18.2 PROTOCOL REVIEWED AND ACCEPTED:

BY: _____ DATE: _____

TITLE: Study Director
FOR: Huntingdon Life Sciences

BY: _____ DATE: _____

Hasmukh C. Shah, Ph.D.

TITLE: Sponsor Representative
FOR: Chemical Manufacturers Association

APPENDIX A

Tissues Preserved/Examined Microscopically

No. #	Tissue	Preserved	Microscopic Examination (Groups)	
			I, IV	II, III
2	adrenals	X		
1	aorta	X		
1	auditory sebaceous glands	X		
1	bone (including joint)	X		
3	brain (cerebrum, brainstem, cerebellum)	X		
1	caecum	X		
2	coagulating glands	X	X	
1	colon	X		
1	duodenum	X		
2	epididymis	X	X	
1	esophagus	X		
2	eyes	X		
1	heart	X		
1	ileum	X		
1	jejunum	X		
2	kidneys	X	X	
2	lacrimal/Hardarian glands	X		
1	larynx	X		
2	liver	X	X	
2	lungs	X	X	
1	mammary glands	X	X	
1	mediastinal lymph nodes	X		
1	mediastinal tissues	X		
1	mesenteric lymph nodes	X		

APPENDIX A
Tissues Preserved/Examined Microscopically

No. ^a	Tissue	Preserved	Microscopic Examination (Groups)	
			I, IV	II, III
1	mesenteric tissues	X		
4	nasal tissues (turbinates)	X	X	
1	oral tissues	X		
1	ovary ^b	X	X	
2	oviducts	X	X	
1	pancreas	X		
2	parathyroid glands	X		
1	peripheral nerve	X		
1	pituitary	X	X	
1	prostate	X	X	
1	rectum	X		
2	salivary glands	X		
2	seminal vesicles	X	X	
1	skeletal muscle	X		
1	skin	X		
3	spinal cord (cervical, thoracic, lumbar)	X		
1	spleen	X		
1	stomach	X		
2	testis	X	X	
1	thymus	X		
2	thyroid gland	X		
1	tongue	X		
1	trachea	X	X	
1	urinary bladder	X		

APPENDIX A

Tissues Preserved/Examined Microscopically

No. ^a	Tissue	Preserved	Microscopic Examination (Groups)	
			I, IV	II, III
2	uterus (body/horns with cervix)	X	X	
1	vagina	X	X	
	gross lesions	X	X	

^a Number of organs/sections preserved/examined.

^b Only the right ovary will be routinely processed for microscopic evaluation. The left ovary will be saved for possible oocyte quantification. If deemed necessary by the sponsor (additional cost), oocyte quantification will include evaluation of a minimum of 10 sections randomly selected from one completely sectioned ovary per female of the high-dose and control groups. Ovarian follicles will be placed into one of three categories as described by Plowchalk et al., (1993). The total number of follicles and the number of follicles in each of the three categories will be evaluated. Ovaries from the low- and mid-dose groups may be evaluated if treatment-related changes are observed in the high-dose group.

APPENDIX B

TEST MATERIAL PROPERTIES

Chemical name	Vinyl chloride
Synonyms	Monochloroethylene, VC, VCM, vinyl chloride monomer
Molecular formula	C_2H_3Cl
Molecular weight	62.5
Structures	$CH_2 = CHCl$
Appearance	Colorless gas
Vapor pressure	2,530 mm Hg at 20 degrees C
Saturated atmosphere	Gas at room temperature
Vapor density	2.16
Flash point	-77.75 degrees C (open cup)
Boiling point	-13.6 degrees C
Specific gravity	0.9121
Conversion factors	$1 \text{ mg/mm}^3 = 0.39 \text{ ppm in air}$